Vibe Rounds — Evidence-Pyramid Trajectory Mapper

RCT TIER · 2 PAPERS · 13 ARM-LEVEL TRAJECTORIES

This tab pools the two RCT-tier papers now processed under the RCTs section: Case 13 (Zeng et al., local ASV vs. chymotrypsin blockade for Naja atra bite necrosis, PLOS Negl Trop Dis 2022 — 2 arms, n=25/25) and Case 14 (Li et al., anfibatide phase I dose-escalation trial, Scientific Reports 2021 — 11 dose-group arms, n=94 randomized/93 analyzed). As with the Unified case insights tab, this does not pool statistics across the two trials — they test unrelated interventions (a local wound-blockade agent vs. an IV platelet-GPIbα antagonist) in unrelated populations (envenomed patients vs. healthy volunteers) — instead it lines up every arm from both trials against the same five-stage RCT schema (Baseline → Allocation/Dosing → Intervention delivery → Primary effect/PD assessment → Disposition) so the two trials' shapes can be compared even though their numbers can't be merged. Toggle any arm on/off below.

Sources: Case 13 Tables 1–3, Fig 1–4; Case 14 Tables 1–2, Figs 4–8.

META-ANALYSIS TIER · 2 PAPERS · 69 STUDY-LEVEL UNITS

This tab does not pool statistics across the two meta-analysis-tier papers now processed under the Meta Analysis section — Case 16 (Afroz et al., global snakebite incidence/mortality, PLoS Negl Trop Dis 2024 — 65 observational studies, continent-level subgroups) and Case 17 (Ganessane et al., fresh frozen plasma for VICC resolution, BMJ Open 2025 — 4 RCT/cohort studies, study-level ORs). They address entirely different questions (descriptive epidemiology of snakebite burden vs. a treatment-effect comparison for one specific complication) and would misrepresent both if merged into one number. What they share structurally, and what this tab is for, is that both are Module F papers: each one's unit of analysis is the included study, not the patient, and each already contains its own internal forest-plot pooling done by the original review authors (Case 16 pools 65 primary studies into 6 continent-level incidence/mortality subgroups plus one global estimate; Case 17 pools 4 studies into one coagulopathy-resolution estimate and, separately, one mortality estimate). Both also flag their own pooled estimates as low/very-low certainty — Case 16 because of I²>75% heterogeneity that no stratification (continent, income tier, study design, study setting) fully explains, and Case 17 because of small sample sizes, methodological risk of bias, and imprecision from low event rates (GRADE: very low). See Case 16 and Case 17 for each paper's full forest-plot-by-outcome breakdown.

SYSTEMATIC REVIEW TIER · 1 PAPER

This tab will hold the cross-paper unified view scoped to the Systematic Review section — currently Case 15 (Das, Sankar & Dev, high-dose vs. low-dose antivenom, Indian Journal of Critical Care Medicine 2015 — 5 pooled RCTs, n=473). As more systematic-review/meta-analysis papers are added to that section, their study-level trajectories will be pooled into this view the same way the Unified case insights tab pools the case-report tier. See the Case 15 tab for the single-paper breakdown in the meantime, including its full forest-plot-by-outcome view.

3 units of analysis (venom samples), each with 6 checkpoint nodes reconstructed from the Case Description (Methods §2) and Results (§3): Collection, Protein Profile, Immunorecognition, Enzymatic Activity, Biological Activity, and Interpretation. No node values were estimated — every figure below is taken directly from the paper's Tables 1–2, Results text, or Figures 1–6.

Hub checkpoints (all 3 trajectories pass through, low divergence)

Collection and Immunorecognition are the hubs: all three samples were obtained from the same animal by the same standardized manual-extraction protocol [Methods §2.1, Grego et al. ref. 15], and all three were well immuno-recognized by anti-Bothrops/Lachesis serum (ABLS) in both Western blot and ELISA, despite statistically significant intensity differences [Results §3, Figures 3–4] — the paper's central "preserved-integrity" claim sits at this hub.

Checkpoints that turned out to be outlier-only

Enzymatic Activity and Biological Activity are where the trajectories fork hardest: Lm_24 (post-mortem) breaks from the Lm_15→Lm_23 pattern on LAAO and PLA₂ (both up), while its coagulant capacity moves the opposite direction from what age alone would predict.

The paper's own conclusion is that the dominant axis of variation is age/senescence, not death: Lm_23 and Lm_24 pattern together against Lm_15 on protein profile and proteolysis, because the Lm_23–Lm_24 gap is only 10 months while the Lm_15–Lm_23 gap is 8 years [Discussion §4, penultimate paragraph].

Sources: Table 1; Results §3 (RP-HPLC/SDS-PAGE description); Discussion §4, citing age-driven variation literature refs. 1, 11, 28, 30.

Three divergence points are the most informative outliers, each named because the paper explicitly separates them from the age-driven "textbook" pattern above:

1. LAAO activity — Lm_24 breaks upward

65.88 ± 1.27 mM/min/mg (Lm_24) vs 53.43 ± 3.54 (Lm_15) and 52.96 ± 2.8 (Lm_23) — Lm_24 is highest even though it does not follow the Lm_23≈Lm_24 age-pairing seen elsewhere. The paper attributes this specifically to post-mortem/storage handling: LAAO is thermolabile, and Lm_24 was frozen only a few weeks versus far longer for the other two [Discussion §4, "L-amino acid oxidase was likely affected by the animal's death," citing refs. 58–61] — a death-linked signal, not an age-linked one.

2. PLA₂ activity — Lm_24 breaks upward

10.8 ± 0.71 U/min/mg (Lm_24) vs 7.96 ± 0.68 (Lm_15) and 6.8 ± 0.78 (Lm_23). The paper flags this as "influenced by post-mortem status" given PLA₂'s disulfide-stabilized structure surviving death intact [Discussion §4, citing ref. 62], while noting ontogeny studies in other genera point both directions (younger vs older higher), so this fork is not simply age noise.

3. Minimum Coagulant Dose & Hemolysis EC₅₀ — Lm_24 diverges from both

MCD: 4.23 ± 0.778 µg/mL plasma (Lm_24, least coagulant) vs 3.03 ± 0.23 (Lm_15) and 2.457 ± 0.161 (Lm_23, most coagulant). Hemolysis EC₅₀: 14 ± 1 µg (Lm_24) vs 24.74 ± 1.45 (Lm_15) and 9.864 ± 0.473 (Lm_23). Lm_24 sits between the other two on both biological assays rather than tracking the Lm_23-paired pattern seen in the protein profile — the paper reads this as the post-mortem sample retaining "coagulant properties within the expected range for the genus" despite being the least potent of the three [Results §3, Table 2; Discussion §4, citing ref. 12].

The paper is explicit that, with n = 1 animal / 3 samples, age and death cannot be statistically disentangled — these are flagged divergences within a single case, not a validated age-vs-death effect [Discussion §4, final paragraph].

Every citation used above, carried forward from the uploaded paper's own bibliography (Tavares et al., 2026, Toxins 18:288):

1. [1] Hamdan, B. et al. When a name changes everything: Taxonomy and conservation of the Atlantic bushmaster (Lachesis Daudin, 1803). Syst. Biodivers. 2024, 22, 2366215.
2. [11] Madrigal, M. et al. Snake venomics across genus Lachesis. Ontogenetic changes in the venom composition of Lachesis stenophrys and comparative proteomics of adult L. melanocephala and L. acrochorda. J. Proteom. 2012, 77, 280–297.
3. [12] Madrigal, M. et al. Cross-reactivity, antivenomics, and neutralization of toxic activities of Lachesis venoms by polyspecific and monospecific antivenoms. PLoS Negl. Trop. Dis. 2017, 11, e0005793.
4. [15] Grego, K.F. et al. Maintenance of venomous snakes in captivity for venom production at Butantan Institute from 1908 to the present: a scoping history. J. Venom. Anim. Toxins Incl. Trop. Dis. 2021, 27, e20200068.
5. [28] Gutiérrez, J. et al. Ontogenetic changes in the venom of the snake Lachesis muta stenophrys (bushmaster) from Costa Rica. Toxicon 1990, 28, 419–426.
6. [30] Moitas, M. et al. Should snakes used in antivenom production be retired? An analysis of Bothrops moojeni venom at different ages. Toxicon 2025, 268, 108624.
7. [58] Du, X.-Y.; Clemetson, K.J. Snake venom L-amino acid oxidases. Toxicon 2002, 40, 659–665.
8. [59] Guo, C. et al. Past decade study of snake venom L-amino acid oxidase. Toxicon 2012, 60, 302–311.
9. [60] Izidoro, L.F.M. et al. Snake Venom L-Amino Acid Oxidases: Trends in Pharmacology and Biochemistry. BioMed Res. Int. 2014, 2014, 196754.
10. [61] Bregge-Silva, C. et al. Isolation and biochemical, functional and structural characterization of a novel L-amino acid oxidase from Lachesis muta snake venom. Toxicon 2012, 60, 1263–1276.
11. [62] Castro-Amorim, J. et al. Catalytically Active Snake Venom PLA2 Enzymes: An Overview of Its Elusive Mechanisms of Reaction. J. Med. Chem. 2023, 66, 5364–5376.

1 unit of analysis (the patient), with 7 checkpoint nodes on the confirmed path reconstructed from the Case Presentation, Investigations, and Treatment and Outcome sections, plus 3 pruned-branch nodes from the Differential Diagnosis / Treatment sections: Onset, Crisis presentation, Diagnostic pivot (with DKA and GBS branches pruned here), ASV decision (with an AChE-inhibitor branch pruned here), Locked-in nadir, Recovery, and Disposition. Every value below is taken directly from the paper's Case Presentation, Table 1, Figure 1 timeline, and Discussion.

Hub / turning-point nodes

The Diagnostic pivot node (hospital day 1–2) is the trajectory's hub: this is where DKA and GBS were actively treated/considered and then excluded on the same node, and where the discovery of "subtle bite marks on the left foot without local reaction" redirected the entire remaining course [Treatment and outcome, para. 1]. The ASV decision node is the second turning point — the only intervention in the whole course associated with eventual (delayed) improvement.

The paper's own Figure 1 timeline is the textbook path for this single case: a hyperacute (~2 hour) descent from abdominal pain to E1V1M1 coma, followed by a 22-day ventilator course and a slow but complete recovery by 3 months [Treatment and outcome; Figure 1].

Sources: Case Presentation; Table 1; Figure 1 timeline; Treatment and outcome section.

Three branch-points are the most informative divergences in this single-patient trajectory — each one a path the team actively started down before the confirmed krait-bite path took over:

1. DKA branch — pruned at HD-2

RBS 352 mg/dL on presentation triggered an insulin infusion (0.1 IU/kg/hr) for suspected diabetic ketoacidosis. It was discontinued on HD-2 once urinary ketones returned negative, HbA1c was normal (4.8%), and glucose normalized [Treatment and outcome, para. 1] — a hyperglycemia red herring the paper explicitly flags as a common misdirection in pediatric EMNS cases [Conclusions; Discussion, citing ref. 14].

2. GBS / demyelinating-disease branch — pruned by imaging + tempo

Normal MRI brain/whole-spine and CSF analysis excluded demyelinating disorders and meningoencephalitis, and the paper argues the ~2-hour onset-to-nadir tempo and preserved early awareness were themselves atypical for Guillain-Barré syndrome, shifting focus toward snakebite/toxin exposure [Treatment and outcome, para. 1; Differential diagnosis section].

3. Acetylcholinesterase-inhibitor branch — tried, ineffective

Neostigmine, pyridostigmine, and calcium infusion were given empirically on HD-2 alongside ASV but produced no clinical response, consistent with the paper's discussion that AChE inhibitors are most effective against postsynaptic neurotoxins (e.g., cobra) and are "controversial and often ineffective, sometimes causing paradoxical worsening" against krait's predominantly presynaptic β-bungarotoxin [Discussion, paragraph on krait venom pharmacology, citing refs. 13, 18, 19].

The paper frames the entire case around this fork structure: bite-to-needle time was 24 hours specifically because of the time spent on the DKA and GBS branches before the bite marks were found, and it argues earlier recognition of the pivot node "may have reduced the duration of ventilation and hospital stay" [Discussion, paragraph 1].

Every citation used above, carried forward from the uploaded paper's own bibliography (Ghanghoriya et al., 2025, Cureus 17(12): e99916):

1. [3] Sasidharan, P.; Kaeley, N.; Mahala, P. et al. Clinical and demographic profiling of snakebite envenomation in a tertiary care centre in northern India. Int. J. Emerg. Med. 2025, 18, 50.
2. [8] Kularatne, S.A. Common krait (Bungarus caeruleus) bite in Anuradhapura, Sri Lanka: a prospective clinical study, 1996–98. Postgrad. Med. J. 2002, 78, 276–280.
3. [11] Daga, M.K.; Kumar, N.; Singh, H. Biomarkers in snakebite: will this be a reality in near future? Indian J. Crit. Care Med. 2025, 29, 104–105.
4. [12] Bawaskar, H.S.; Bawaskar, P.H.; Bawaskar, P.H. Premonitory signs and symptoms of envenoming by common krait (Bungarus caeruleus). Trop. Doct. 2014, 44, 82–85.
5. [13] Bickler, P.E.; Abouyannis, M.; Bhalla, A.; Lewin, M.R. Neuromuscular weakness and paralysis produced by snakebite envenoming: mechanisms and proposed standards for clinical assessment. Toxins (Basel) 2023, 15, 49.
6. [14] Samprathi, M.; Gupta, V.; Jayashree, M.; Bansal, A.; Baranwal, A.; Nallasamy, K. Epidemiology and outcomes of early morning neuroparalytic syndrome following snake bite — a retrospective study. J. Trop. Pediatr. 2020, 66, 435–440.
7. [15] Anadure, R.K.; Narayanan, C.S.; Hande, V.; Singhal, A.; Varadaraj, G. Two cases of early morning neuroparalytic syndrome (EMNS) in the tropics — masquerading as brain death. J. Assoc. Physicians India 2018, 66, 92–95.
8. [16] World Health Organization. Guidelines for the management of snakebites, 2nd edition. 2016.
9. [18] Anil, A.; Singh, S.; Bhalla, A.; Sharma, N.; Agarwal, R.; Simpson, I.D. Role of neostigmine and polyvalent antivenom in Indian common krait (Bungarus caeruleus) bite. J. Infect. Public Health 2010, 3, 83–87.
10. [19] Karthika, I.K.; Satapathy, A.K. Neurotoxic snake envenomation: neostigmine-induced paradoxical weakness. Indian J. Pediatr. 2021, 88, 406.
11. [20] Mehta, V.; Kumar, R.; Prabhakar, R.; Sharma, C.B.; Thomas, A. Dramatic neuromuscular paralysis following occult snakebites. An awareness for the primary care physician. J. Family Med. Prim. Care 2022, 11, 386–389.

1 unit of analysis (the patient), with 6 checkpoint nodes taken directly from the paper's own Table 1 timeline and Case Presentation/Discussion text: Bite & initial ASV, CS presentation, Fasciotomy, Second-look debridement, Progressive closure, and Disposition — plus one contested branch, Antivenom-alone management, representing the literature position the paper argues against in this case.

Hub / turning-point nodes

The CS presentation node (Day 2) is the trajectory's hub: this is where the paper explicitly notes the diagnosis was clinical, made "in the absence of compartment pressure monitoring" [Introduction, para. 2] — the single most consequential and most explicitly flagged-as-uncertain decision point in the case. Fasciotomy (also Day 2) is the second hub: the paper frames it as the point where the case diverges from the antivenom-first literature default because "despite timely antivenom administration, signs of CS remained" [Discussion, para. 5].

The paper's own Table 1 timeline is the textbook path for this case: a green pit viper bite treated with ASV and discharged at 24 hours, followed by Day-2 deterioration, emergency fasciotomy, and a 20-day staged-closure recovery to full hand function [Table 1; Case presentation].

Sources: Table 1; Case presentation section; Discussion, para. 6 (transfusion detail).

Unlike Case 2's pruned diagnostic branches, this case has one clearly named contested treatment branch rather than a wrong diagnosis: the paper explicitly frames current literature as holding that fasciotomy should be reserved for cases unresponsive to antivenom, since early ASV "can effectively control elevated compartment pressures in many cases" [Discussion, para. 5, citing refs. 7, 10]. In this patient that branch was tried first (10 vials ASV, Day 0) and failed to prevent CS by Day 2, which the authors use as their central argument for earlier, suspicion-based fasciotomy even without pressure monitoring [Conclusion, final paragraph]. The paper also names specific risk markers associated with this branch failing — leukocytosis, high INR, and elevated AST — as factors reported elsewhere to predict CS despite antivenom [Discussion, para. 4, citing ref. 8], all of which this patient had (WBC 10,900/mm³, INR 2.7).

The paper is explicit that this remains an open evidentiary gap, not a settled protocol: it closes by calling for "future studies... to establish clear guidelines for the timing and criteria of fasciotomy in snakebite-associated compartment syndrome" [Conclusion, final sentence] — i.e., the branch-point itself is acknowledged as unresolved by the field, not just by this one case.

Every citation used above, carried forward from the uploaded paper's own bibliography (Bhattarai et al., 2025, Ann. Med. Surg. 87:6197–6200):

1. [1] Snakebite envenoming. World Health Organization. Accessed 15 Oct 2024. https://www.who.int/news-room/fact-sheets/detail/snakebite-envenoming.
2. [2] Navaeifar, M.R.; Zakariaei, Z.; Ghadiri, A. et al. Compartment syndrome following snakebite in a boy: a case report and literature review. Int. J. Surg. Case Rep. 2023, 105, 108050.
3. [3] Sohrabi, C.; Mathew, G.; Maria, N. et al. The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines. Int. J. Surg. 2023, 109, 1136.
4. [7] Sassoè-Pognetto, M.; Cavalcante, R.; Paonessa, M. Acute compartment syndrome and fasciotomy after a viper bite in Italy: a case report. Ital. J. Pediatr. 2024, 50, 70.
5. [8] Hsu, C.P.; Chuang, J.F.; Hsu, Y.P. et al. Predictors of the development of post-snakebite compartment syndrome. Scand. J. Trauma Resusc. Emerg. Med. 2015, 23, 97.
6. [9] Merle, G.; Harvey, E.J. Pathophysiology of compartment syndrome. In Compartment Syndrome: A Guide to Diagnosis and Management; Mauffrey, C., Hak, D.J., Martin, M.P., Eds.; Springer: Cham, 2019.
7. [10] Newman, J.; Therriault, C.; White, M.S. et al. Compartment syndrome following snake envenomation in the United States: a scoping review of the clinical literature. West J. Emerg. Med. 2024, 25, 651–660.
8. [11] Cavazos, D.R.; Schultz, R.; Higginbotham, D.O. et al. Refractory compartment syndrome after antivenom administration for an eastern diamondback rattlesnake bite requiring fasciotomy for limb salvage: a case report. Trauma Case Rep. 2023, 46, 100852.
9. [12] Kim, Y.H.; Hee, C.J.; Kim, J. et al. Fasciotomy in compartment syndrome from snakebite. Arch. Plast. Surg. 2019, 46, 69–74.

5 units of analysis (the five ED patients), each with 6 checkpoint nodes reconstructed from the paper's own per-case narratives (Case Presentation, Cases 1–5): Presentation, Syndrome/diagnosis, Initial ASV, Escalation, Advanced intervention, and Disposition. No values were estimated — every figure below is taken directly from each numbered case narrative and the Discussion's own cross-case tally.

Hub checkpoints (all 5 trajectories pass through)

Initial ASV is the strongest hub: all five patients received an identical opening dose of 10 vials of anti-snake venom regardless of syndrome type [Cases 1–5, each opening management paragraph]. Escalation is a near-hub: 4 of 5 patients required a second 10-vial ASV dose for a persisting/worsening finding (compartment syndrome, coagulopathy ×2, thrombocytopenia) — only Case 3's second dose was paired with FFP rather than a distinct complication.

Checkpoints that turned out to be outlier-only

Advanced intervention is where the trajectories fork hardest: only Cases 1 and 5 required renal replacement therapy, and only Case 1 escalated further to plasmapheresis for suspected atypical HUS — no recovered patient (Cases 2–4) needed dialysis or transfusion-level intervention at all.

Three of five patients follow the same shape: syndrome identified early (neurotoxic or coagulopathic), managed with an initial 10-vial ASV dose, a single second 10-vial dose when labs or clinical signs persisted, no renal replacement or transfusion escalation, and discharge with recovery inside 2–10 days [Discussion, para. 2, "Two patients underwent hemodialysis... two patients succumbed" — by elimination, the other three did not].

Sources: Case Presentation, Cases 2–4 narratives.

Cases 1 and 5 are the paper's own named outliers — both are the only two of five patients who died [Discussion, para. 2, "two patients succumbed"] — and both diverge from the textbook path at the same checkpoint (Advanced intervention), but for different reasons:

1. Case 1 (36M) — renal-first fork into suspected atypical HUS

Initially the mildest-looking presentation (mild pain, minimal bleeding, normal Day-1 renal/coagulation labs) [Case 1, para. 1], but forked sharply on Day 2 (impending compartment syndrome → fasciotomy + second 10-vial ASV dose) and again on Day 4 (anuric, 6 cycles hemodialysis), then forked a second time into a distinct outlier branch not seen in any other case: worsening coagulopathy with schistocytes on peripheral smear raised suspicion for atypical hemolytic uremic syndrome, prompting 4 cycles of plasmapheresis plus 5 cycles of SLED [Case 1, para. 1]. Died Day 14 of pulmonary edema despite non-invasive ventilation; post-mortem renal biopsy confirmed severe acute tubular necrosis [Case 1, final paragraph; Figure 1].

2. Case 5 (38M) — delayed presentation + non-standard exposure + relapse after discharge

The only patient in the series with a non-standard mechanism (bilateral hand bites sustained while handling the snake under the influence of alcohol) [Case 5, para. 1] and the only delayed presentation (3 days, after first being treated at a local ayurvedic center — a pruned first-line branch outside the ASV pathway entirely) [Case 5, para. 1]. Diagnosed with viper-induced consumptive coagulopathy (VICC), managed with transfusion + additional ASV + hemodialysis, and appeared to recover — discharged Day 11 on hemodialysis follow-up. The trajectory then forks a second time after apparent resolution: readmitted Day 20 with flash pulmonary edema attributed explicitly to hemodialysis non-compliance, intubated, and died Day 21 [Case 5, paragraphs 2–3] — the only relapse-after-discharge trajectory in the series.

The paper's own cross-case tally anchors this reading: of five patients, "two patients underwent hemodialysis for acute kidney injury and two patients underwent fasciotomies for compartment syndrome... two patients succumbed" [Discussion, para. 2] — Case 1 is the patient counted in both the dialysis and fasciotomy tallies, making it the single most intervention-dense trajectory in the series as well as its most severe outcome.

Every citation used above, carried forward from the uploaded paper's own bibliography (Mahadevaiah et al., 2024, Cureus 16(1): e53319):

1. [1] Gutiérrez, J.M.; Calvete, J.J.; Habib, A.G.; Harrison, R.A.; Williams, D.J.; Warrell, D.A. Snakebite envenoming. Nat. Rev. Dis. Primers 2017, 3, 17063.
2. [2] Mohapatra, B.; Warrell, D.A.; Suraweera, W. et al. Snakebite mortality in India: a nationally representative mortality survey. PLoS Negl. Trop. Dis. 2011, 5, e1018.
3. [3] Pradniwat, P.; Rojnuckarin, P. Snake venom thrombin-like enzymes. Toxin Rev. 2014, 33, 16–22.

1 unit of analysis (the patient), with 7 checkpoint nodes on the confirmed path reconstructed from the Case Report and Discussion sections, plus 5 pruned-branch nodes (grouped as one differential-workup cluster) from the same paragraph: Bite, ED crisis presentation, ASV + ventilatory support, Acute discharge, Delayed re-presentation (with dengue, ARF, scarlet fever, IgA vasculitis and SJS branches pruned here), Serum-sickness diagnosis, and Steroid taper / disposition. Every value below is taken directly from the paper's Case Report and Discussion sections — no figures were estimated.

Hub / turning-point nodes

The Delayed re-presentation node (hospital day 9 post-bite, 6 days after discharge) is the trajectory's hub: this is where five differentials were actively worked up and excluded on the same node before complement and CRP testing redirected the diagnosis [Case Report, para. 3]. The Serum-sickness diagnosis node (low C3/C4 + raised CRP) is the second turning point — the paper's own central finding and the only node in the whole file with a named laboratory-defined diagnostic threshold.

The paper's own two-paragraph Case Report is the textbook path for this single case: a hyperacute neurotoxic envenomation resolved with high-dose ASV and 36 hours of mechanical ventilation, followed by an apparently clean 3-day discharge, then a second, immune-mediated illness emerging 9 days after the original bite [Case Report, paras. 1–3].

Sources: Case Report paragraphs 1–4.

At the Day-9 re-presentation, five differentials were actively considered and then excluded on the same node before the complement/CRP panel redirected the diagnosis toward serum sickness [Case Report, para. 3]:

1. Dengue fever — pruned by negative serology

Complete blood picture was normal and dengue serology was negative, explicitly negating dengue fever as the differential [Case Report, para. 3].

2. Acute rheumatic fever, scarlet fever & IgA vasculitis — pruned by absence of supporting features

The patient had no history of fever or exanthem, which the authors cite as part of the reasoning ruling out this cluster of differentials alongside dengue [Case Report, para. 3].

3. Stevens-Johnson syndrome — pruned by absence of mucocutaneous findings

Listed among the differentials "ruled out" in the same sentence as the others, consistent with the absence of any rash/exanthem on exam [Case Report, para. 3].

The paper frames the whole delayed-presentation node around this pruning process: it is the combination of a recent snakebite/ASV history, low complement (C3, C4) and raised CRP — not any single differential's exclusion alone — that the authors state "confirmed" the serum-sickness diagnosis [Case Report, para. 3], and the Discussion separately notes that the incidence of serum sickness after ASV use had never previously been documented in India before this report [Discussion, para. 3, citing ref. 6].

Every citation used above, carried forward from the uploaded paper's own bibliography (Guru et al., 2024, J Family Med Prim Care 13:2792–4):

1. [1] Suraweera W, Warrell D, Whitaker R, Menon G, Rodrigues R, Fu SH, et al. Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study. Elife 2020, 9:e54076.
2. [3] de Silva HA, Ryan NM, de Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment. Br J Clin Pharmacol 2016, 81:446-52.
3. [5] Lavonas EJ, Kokko J, Schaeffer TH, Mlynarchek SL, Bogdan GM, Dart RC. Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite. Ann Emerg Med 2011, 57:128-37.
4. [6] Deshpande RP, Motghare VM, Padwal SL, Pore RR, Bhamare CG, Deshmukh VS, et al. Adverse drug reaction profile of anti-snake venom in a rural tertiary care teaching hospital. J Young Pharm 2013, 5:41-5.
5. [7] León G, Herrera M, Segura Á, Villalta M, Vargas M, Gutiérrez JM. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms. Toxicon 2013, 76:63-76.
6. [8] LoVecchio F, Klemens J, Roundy EB, Klemens A. Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ Med 2003, 14:220-1.
7. [9] Ryan NM, Kearney RT, Brown SG, Isbister GK. Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22). Clin Toxicol (Phila) 2016, 54:27-33.
8. [10] Ahmed SM, Ahmed M, Nadeem A, Mahajan J, Choudhary A, Pal J. Emergency treatment of a snake bite: Pearls from literature. J Emerg Trauma Shock 2008, 1:97-105.
9. [11] Huang CY, Hung DZ, Chen WK. Antivenin-related serum sickness. J Chin Med Assoc 2010, 73:540-2.
10. [12] Morais V, Massaldi H. Effect of pepsin digestion on the antivenom activity of equine immunoglobulins. Toxicon 2005, 46:876-82.
11. [13] León G, Monge M, Rojas E, Lomonte B, Gutiérrez JM. Comparison between IgG and F(ab')(2) polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions. Toxicon 2001, 39:793-801.
12. [14] Madhushani U, Thakshila P, Hodgson WC, Isbister GK, Silva A. Effect of Indian polyvalent antivenom in the prevention and reversal of local myotoxicity induced by common cobra (Naja naja) venom from Sri Lanka In Vitro. Toxins (Basel) 2021, 13:308.

1 unit of analysis (the patient), with 7 checkpoint nodes on the confirmed path reconstructed from the Case Report, plus 1 pruned-branch node from the Discussion: Unwitnessed bite, ED crisis presentation, Initial ASV + anticholinesterase, Hepatotoxicity discovery (with a hepatic-serology differential branch pruned here), ASV escalation + Vitamin K/FFP, Recovery, and Disposition. Every value below is taken directly from the paper's Case Report section — no figures were estimated.

Hub / turning-point nodes

The Hepatotoxicity discovery node (deranged LFT sent as part of routine relevant-investigations workup) is the trajectory's hub: this is where the paper's central, publication-worthy finding surfaces, and where hepatic serology was actively sent and excluded on the same node to confirm the derangement was venom-linked rather than incidental [Case Report, para. 2]. The ASV escalation node is the second turning point — a second 10-vial dose given specifically because the child "did not show much improvement" on the first dose, after which both the neurological and hepatic pictures began to resolve together [Case Report, para. 2].

The paper's own single Case Report paragraph is the textbook path for this case: a hyperacute neurotoxic collapse (found unconscious at home, GCS 4/15) resolved with two rounds of ASV and anticholinesterase therapy, with a rare hepatotoxic injury discovered, actively worked up, and resolved in parallel [Case Report, paras. 1–2].

Sources: Case Report, paragraphs 1–2.

At the Hepatotoxicity discovery node, one alternative explanation was actively worked up and excluded before the derangement was attributed to venom:

1. Non-venom hepatic causes (viral/other hepatic serology) — pruned by negative serology

The authors state they "carried out other investigations to rule out any other possible causes of hepatic injury" given the child had no previous history of co-morbidity; hepatic serology was sent and returned negative [Discussion, para. 1; Case Report, para. 2], leaving snake envenomation as the attributed cause — consistent with the Discussion's review of animal studies showing elapid venoms (Egyptian cobra, black-necked spitting cobra) directly inducing hepatic histopathological damage, coagulative necrosis, and AST/ALT elevation via cell-membrane permeability changes [Discussion, citing refs. 5–13].

The paper frames its whole contribution around this branch: Elapid bites are conventionally taught as purely neurotoxic with little/no systemic organ damage beyond the nervous system, so the deliberate exclusion-then-attribution sequence at this node is what lets the authors argue hepatotoxicity "must not be overlooked" and that suspected snake bites should be investigated "thoroughly... in all spheres" rather than assumed to fit the textbook single-system pattern [Discussion, final paragraph; Conclusion].

Every citation used above, carried forward from the uploaded paper's own bibliography (Chaudhuri et al., 2025, J Family Med Prim Care 14:2062–4):

1. [1] Rajakumar PS, Singaravelu M, Nakate D. Standard Treatment Guideline, Snake Bite Edition 2022. New Delhi: Indian Academy of Pediatrics; 2022. Chapter 102. p. 3.
2. [2] Ghai OP. Ghai Essential Pediatrics: Poisoning Injuries and Accidents. 10th ed. Delhi: CBS Publishers; 2023. p. 757.
3. [3] World Health Organization. Guidelines for the Management of Snakebites. World Health Organization; 2016. p. 15.
4. [4] Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, editors. Nelson Textbook of Pediatrics. Envenomations, 21st ed. Philadelphia: Elsevier; 2020. p. 3822.
5. [5] Imam AH, Rahmy TR. Reactive astrocytic response and increased proliferative cell nuclear antigen expression in cerebral cortex of envenomated rats. J Toxicol Toxin Rev 2001, 20:245-59.
6. [6] Rahmy TR, Hemmaid KZ. Histological and histochemical alterations in the liver following intramuscular injection with a sublethal dose of the Egyptian cobra venom. J Nat Toxins 2000, 9:21-32.
7. [7] Abdel Moneim AE, Othman MS, Mohmoud SM, El-Deib KM. Pomegranate peel attenuates aluminum-induced hepatorenal toxicity. Toxicol Mech Methods 2013, 23:624-33.
8. [8] Omale J, Ebiloma G, Idoko GO. In vivo neutralization of Naja nigricollis venom by Uvaria chamae. Am J Biochem Biotechnol 2013, 9:224-34.
9. [9] Omran MA, Fabb SA, Dickson G. Biochemical and morphological analysis of cell death induced by Egyptian cobra (Naja haje) venom on cultured cells. J Venom Anim Toxins Incl Trop Dis 2004, 10:219-41.
10. [11] Doley R, Mukherjee AK. Purification and characterization of an anticoagulant phospholipase A2 from Indian monocled cobra (Naja kaouthia) venom. Toxicon 2003, 41:81-91.
11. [12] Tohamy AA, Mohamed AF, Moneim AE, Diab MS. Biological effects of Naja haje crude venom on the hepatic and renal tissues of mice. J King Saud Univ-Sci 2014, 26:205-12.
12. [13] Kurfi BG, Ibrahim HM, Abdulazeez AM. Histopathological studies on effect of serum liver enzymes of Naja nigricollis and Bitis arietans venom. Sci World J 2021, 16:436-40.
13. [14] Sankar J, Lodha Rakesh, Kabra SK. Pediatric Intensive Care Protocols of AIIMS, Management of Snake Bite. 8th ed. Indian Journal of Pediatrics, New Delhi Publ; 2022. p. 503.

1 unit of analysis (the patient), with 7 checkpoint nodes on the confirmed path reconstructed from the Case Report, plus 2 unresolved-mechanism nodes from the Discussion: Farm bite (right foot), Seizure en route (with a two-hypothesis branch pruned here — see below), ED crisis presentation + SESS grading, Initial ASV (10 vials), Gács sign on CT (hub), ASV re-administration (5 vials), and Disposition. Every value below is taken directly from the paper's Case Report section — no figures were estimated.

Hub / turning-point nodes

The Gács sign on CT node (non-contrast brain CT at 6 hours post-admission, showing hyperattenuation of the right MCA without infarction) is the trajectory's hub — it is the paper's central, publication-worthy finding, and the point that triggers guideline-directed ASV re-administration 12 hours later [Case Report, para. 3]. The Seizure en route node is the second turning point: a generalized seizure controlled with midazolam during transfer, deliberately dosed low and short-acting so as not to interfere with the neurological exam that would drive antivenom decision-making [Case Report, para. 1].

The paper's own Case Report is the textbook path for this case: a severe envenomation (SESS grade "very severe") with a hyperacute seizure and unconsciousness, treated with early polyvalent antivenom, in which a clinically silent MCA thrombotic occlusion was discovered on routine post-admission imaging, re-treated per guideline, and had fully reversed by day 3 with no residual neurological deficit [Case Report, paras. 1–4].

Sources: Case Report, paragraphs 1–4; Table 1; Figures 1–3.

At the Seizure en route node, the authors searched the literature for a precedent and found none for seizures following M. lebetina bites specifically, then proposed — and explicitly left unadjudicated — two possible mechanisms:

1. Cortical hypoxia secondary to MCA clot obstruction — proposed, not confirmed

The seizure could reflect swift-onset cortical hypoxia from the same thrombotic process later visualized as the Gács sign, i.e., a direct consequence of the vascular occlusion itself [Discussion, para. 6].

2. Direct seizure-inducing (neurotoxic) effect of venom phospholipase A2 — proposed, not confirmed

Alternatively, the authors hypothesize the seizure could stem from the venom's own phospholipase A2 (PLA2) content — among the most prevalent and neurotoxic protein components of M. lebetina venom — independent of the vascular clot, drawing an analogy to PLA2-linked neurotoxicity and status epilepticus reported after other viperid bites (e.g., Russell's viper) despite viperid venoms being conventionally classified as hemotoxic rather than neurotoxic [Discussion, paras. 4–6, citing refs. 18–20, 23–24].

Unlike the exclude-then-attribute branches in Cases 5 and 6, the authors do not resolve which mechanism (or whether both) produced the seizure — they present this as the paper's own acknowledged gap, framing it as a direction for future study rather than a settled finding [Discussion, para. 6; Conclusion].

Every citation used above, carried forward from the uploaded paper's own bibliography (Mirakbari & Gorji, 2025, Arch Iran Med 28(4):240–243, doi: 10.34172/aim.31131):

1. [1] Dehghani R, Dadpour B, Mehrpour O. Epidemiological profile of snakebite in Iran, 2009-2010 based on information of Ministry of Health and Medical Education. Int J Med Toxicol Forensic Med. 2014;4(2):33-41.
2. [2] Huang YK, Chen YC, Liu CC, Cheng HC, Tu AT, Chang KC. Cerebral complications of snakebite envenoming: case studies. Toxins (Basel). 2022;14(7):436.
3. [3] Paul G, Paul BS, Puri S. Snake bite and stroke: our experience of two cases. Indian J Crit Care Med. 2014;18(4):257-8.
4. [4] Monzavi SM, Dadpour B, Afshari R. Snakebite management in Iran: devising a protocol. J Res Med Sci. 2014;19(2):153-63.
5. [5] Pothukuchi VK, Kumar A, Teja C, Verma A. A rare case series of ischemic stroke following Russell's viper snake bite in India. Acta Med Indones. 2017;49(4):343-6.
6. [6] Narang SK, Paleti S, Azeez Asad MA, Samina T. Acute ischemic infarct in the middle cerebral artery territory following a Russell's viper bite. Neurol India. 2009;57(4):479-80.
7. [7] Sahoo AK, Sriramka B. Acute reversible ischemic stroke after snake bite. Indian J Crit Care Med. 2018;22(8):611-2.
8. [8] Gawarammana I, Mendis S, Jeganathan K. Acute ischemic strokes due to bites by Daboia russelii in Sri Lanka - first authenticated case series. Toxicon. 2009;54(4):421-8.
9. [9] Zeng X, Hu J, Liang X, Wu Y, Yan M, Zhu M, et al. Acute cerebral infarction following a Trimeresurus stejnegeri snakebite: a case report. Medicine (Baltimore). 2019;98(23):e15684.
10. [10] Mosquera A, Idrovo LA, Tafur A, Del Brutto OH. Stroke following Bothrops spp. snakebite. Neurology. 2003;60(10):1577-80.
11. [11] Jeevagan V, Chang T, Gnanathasan CA. Acute ischemic stroke following hump-nosed viper envenoming; first authenticated case. Thromb J. 2012;10(1):21.
12. [12] Simpson CH, Richardson WH, Swartzentruber GS, Lloyd VJ. ST segment elevation myocardial infarction following a Crotalus horridus envenomation. Wilderness Environ Med. 2018;29(3):383-7.
13. [13] Farid TM, Tu AT, el-Asmar MF. Characterization of cerastobin, a thrombin-like enzyme from the venom of Cerastes vipera (Sahara sand viper). Biochemistry. 1989;28(1):371-7.
14. [14] Basheer AR, El-Asmar MF, Soslau G. Characterization of a potent platelet aggregation inducer from Cerastes cerastes (Egyptian sand viper) venom. Biochim Biophys Acta. 1995;1250(1):97-109.
15. [15] Dekhil H, Wisner A, Marrakchi N, El Ayeb M, Bon C, Karoui H. Molecular cloning and expression of a functional snake venom serine proteinase, with platelet aggregating activity, from the Cerastes cerastes viper. Biochemistry. 2003;42(36):10609-18.
16. [16] Murthy JM, Kishore LT, Naidu KS. Cerebral infarction after envenomation by viper. J Comput Assist Tomogr. 1997;21(1):35-7.
17. [17] Thomas L, Tyburn B, Ketterlé J, Biao T, Mehdaoui H, Moravie V, et al. Prognostic significance of clinical grading of patients envenomed by Bothrops lanceolatus in Martinique. Trans R Soc Trop Med Hyg. 1998;92(5):542-5.
18. [18] Silva A, Maduwage K, Sedgwick M, Pilapitiya S, Weerawansa P, Dahanayaka NJ, et al. Neurotoxicity in Russell's viper (Daboia russelii) envenoming in Sri Lanka: a clinical and neurophysiological study. Clin Toxicol (Phila). 2016;54(5):411-9.
19. [19] Lahiri D, Sawale VM, Dubey S, Roy BK, Das SK. Status epilepticus and bilateral middle cerebral artery infarction: a rare presentation after viper bite. Ann Afr Med. 2019;18(2):111-4.
20. [20] Osipov A, Utkin Y. What are the neurotoxins in hemotoxic snake venoms? Int J Mol Sci. 2023;24(3):2919.
21. [21] Kazemi SM, Al-Sabi A, Long C, Shoulkamy MI, Abd El-Aziz TM. Case report: recent case reports of levant blunt-nosed viper Macrovipera lebetina obtusa snakebites in Iran. Am J Trop Med Hyg. 2021;104(5):1870-6.
22. [22] Sharma LR, Lal V, Simpson ID. Snakes of medical significance in India: the first reported case of envenoming by the Levantine viper (Macrovipera lebetina). Wilderness Environ Med. 2008;19(3):195-8.
23. [23] Siigur J, Aaspõllu A, Siigur E. Biochemistry and pharmacology of proteins and peptides purified from the venoms of the snakes Macrovipera lebetina subspecies. Toxicon. 2019;158:16-32.
24. [24] Dorandeu F, Pernot-Marino I, Veyret J, Perrichon C, Lallement G. Secreted phospholipase A2-induced neurotoxicity and epileptic seizures after intracerebral administration: an unexplained heterogeneity as emphasized with paradoxin and crotoxin. J Neurosci Res. 1998;54(6):848-62.
25. [25] Gács G, Fox AJ, Barnett HJ, Vinuela F. CT visualization of intracranial arterial thromboembolism. Stroke. 1983;14(5):756-62.
26. [26] Jensen-Kondering U, Riedel C, Jansen O. Hyperdense artery sign on computed tomography in acute ischemic stroke. World J Radiol. 2010;2(9):354-7.

2 units of analysis (the two ED patients), each with 6 checkpoint nodes reconstructed from the paper's own per-case narratives and Fig. 2's own summary timeline: Presentation, Traditional-healer delay, Initial/escalating ASV, Complication development, ICU + dialysis, and Disposition. Every value below is taken directly from the paper's Case report 1/2 narratives and Fig. 2 — no figures were estimated.

Hub checkpoints (both trajectories pass through)

Traditional-healer delay is the paper's own named hub — both patients' families sought an ojha before any hospital contact, and the authors frame this as the upstream cause of the downstream complications in both cases [Discussion, para. 1, citing ref. 3: "61% of victims were reported seeking immediate care from these ojhas"]. ASV administration and ICU + dialysis are near-hubs: both patients received antivenom and both required dialysis for acute kidney injury, though the dose and session counts diverge sharply (see below).

Checkpoints that turned out to be outlier-only

Complication development and Disposition are where the two trajectories fork hardest: only Case 2 developed pancytopenia and respiratory distress requiring mechanical ventilation, and only Case 2's hospitalization ran to 26 days versus Case 1's 7.

Both patients follow the same overall shape — bite → traditional-healer detour → escalating hospital referral chain → repeated ASV dosing → ICU/dialysis for AKI and coagulopathy → full recovery with no residual disability — which the authors frame as itself noteworthy: full survival from severe Russell's-viper envenomation with multiorgan complications is "scarce in low resource settings" [Abstract, final sentence].

Sources: Case report 1; Case report 2; Fig. 2 (case summary timeline).

Case 2 (35M) — longer delay, more severe multiorgan course

Case 2's 58-hour delay to first ASV (versus Case 1's 18 hours) is paired with the series' only occurrence of near-total platelet consumption (6,000/mm³), the higher creatinine (6.09 vs. 3.77 mg/dL), the only respiratory failure requiring intubation and 7 days of mechanical ventilation, the highest cumulative ASV dose (40 vials across 4 doses), and by far the longest hospitalization (26 days vs. 7) [Case report 2, paragraphs 1–3]. The authors explicitly connect the two patients' outcomes to their differential delay: "delayed administration of antivenom, in both cases, led to these severe complications" [Discussion, para. 3], using the pair as their central evidentiary example rather than treating either case in isolation.

Despite the more severe course, Case 2 still converges onto the same "no residual disability" disposition node as Case 1 — the paper's headline point is that both survived, which it frames as atypical for low-resource settings, rather than that delay predicts mortality outright [Abstract; Conclusion].

Every citation used above, carried forward from the uploaded paper's own bibliography (Sharif et al., 2024, J Med Case Rep 18:56, doi: 10.1186/s13256-024-04354-0):

1. [1] Chippaux JP. Snakebite envenomation turns again into a neglected tropical disease! J Venom Anim Toxins Including Trop Dis. 2017;23:38.
2. [2] Ahsan F, Saeed A. Russell's Viper (Daboia Russelii) in Bangladesh: its boom and threat to human life. J Asiat Soc Bangladesh Sci. 2018;44(1):15-22.
3. [3] Hossain J, Biswas A, Rahman F, Mashreky SR, Dalal K, Rahman A. Snakebite epidemiology in Bangladesh—a national community based health and injury survey. Health. 2016;08(05):479-86.
4. [4] Hasan MN, Azam NK, Ahmed MN, Hirashima A. A randomized ethnomedicinal survey of snakebite treatment in southwestern parts of Bangladesh. J Tradit Complement Med. 2016;6(4):337-42.
5. [5] Subedi B. Perspective chapter: integrating traditional healers into the National Health Care System—a review and reflection. In: Rural health—investment, research and implications. IntechOpen; 2023.
6. [6] Madamombe I. Traditional healers boost primary health care. Afr Renew. 2006;19(4):10-1.
7. [7] Steinhorst J, Aglanu LM, Ravensbergen SJ, Dari CD, Abass KM, Mireku SO, et al. 'The medicine is not for sale': practices of traditional healers in snakebite envenoming in Ghana. PLoS Negl Trop Dis. 2021;15(4):e0009298.
8. [8] Steinhorst J, Tianyi FL, Habib AG, Oluoch GO, Lalloo DG, Stienstra Y. Uniting behind a common goal: collaboration between traditional healers and allopathic health care workers to improve rural snakebite care. Toxicon X. 2022;16:100140.
9. [9] Siddique MAB, Rahman MM, Kabir HAKM, Mallik MU, Habibullah M, Hassan MM, et al. Experience of managing snake bite cases in a medicine unit of tertiary care hospital in Bangladesh—a case series. J Med (Bangladesh). 2021;22(1):72-6.
10. [10] Banerjee R. Epidemiology and clinical features of snake bite induced acute kidney injury patients in last decade and its longterm outcome—a single center experience. Indian J Appl Res. 2022.
11. [11] Hung DZ, Yu YJ, Hsu CL, Lin TJ. Antivenom treatment and renal dysfunction in Russell's viper snakebite in Taiwan: a case series. Trans R Soc Trop Med Hyg. 2006;100(5):489-94.
12. [12] Alfred S, Bates D, White J, Mahmood MA, Warrell DA, Thwin KT, et al. Acute kidney injury following Eastern Russell's Viper (Daboia siamensis) snakebite in Myanmar. Kidney Int Rep. 2019;4(9):1337-41.
13. [13] Hasan SMK, Basher A, Molla AA, Sultana NK, Faiz MA. The impact of snake bite on household economy in Bangladesh. Trop Doct. 2012;42(1):41-3.

1 unit of analysis (the patient), with 6 checkpoint nodes reconstructed from the paper's own Case Presentation and Figure 3 timeline, plus 1 pruned-branch node from the Discussion: Bite & collapse, Local hospital: ASV + intubation, Tertiary transfer: VICC management, Stroke onset (hub) (with a conventional-etiology differential branch pruned here), Antiplatelet therapy + recovery, and Disposition. Every value below is taken directly from the paper's Case Presentation section and Table 1/Figure 3 — no figures were estimated.

Hub / turning-point nodes

The Stroke onset node (Day 2 ptosis/ophthalmoplegia → Day 4 MRI-confirmed multi-territorial infarcts) is the trajectory's hub — it is the paper's central, publication-worthy finding, and the point at which the conventional stroke differential is actively worked up and excluded before the authors attribute the infarcts to venom-induced thrombotic microangiopathy [Discussion, final two paragraphs]. The Tertiary transfer: VICC management node is the second turning point: bedside WBCT remained abnormal after 8 hours and two ASV doses, prompting a third 10-vial dose plus transfusion support, after which the coagulation profile finally began to normalize by 24 hours [Case Presentation, para. 3; Table 1].

The paper's own Case Presentation and Figure 3 timeline is the textbook path for this case: a hyperacute collapse with respiratory distress and abnormal WBCT, three escalating doses of ASV plus transfusion support to control VICC, a Day-2 to Day-4 emergence of multi-territorial ischemic stroke actively worked up against conventional causes, and gradual improvement with dual antiplatelet therapy, extubation on Day 7, and residual aphasia requiring structured rehabilitation [Case Presentation, paras. 1–6; Figure 3].

Sources: Case Presentation, paragraphs 1–6; Table 1; Figures 1–3.

At the Stroke onset node, several conventional stroke mechanisms were actively investigated and excluded before the infarcts were attributed to venom-induced thrombotic microangiopathy:

1. Cardioembolism — pruned by echocardiogram

2D echocardiogram showed no valvular pathology or intracardiac thrombus [Case Presentation, para. 6].

2. Large-vessel atherosclerosis — pruned by Doppler + lipid/homocysteine studies

Carotid and vertebral artery Doppler studies were unremarkable, and lipid profile and serum homocysteine were within normal limits; the patient was a lifelong non-smoker with no alcohol use [Case Presentation, para. 6].

3. Vasculitis / watershed infarction — pruned by imaging pattern

Imaging revealed no evidence of watershed infarcts or vasculitis, and infarctions occurred rapidly within 24–48 hours of envenomation, which the authors argue supports an acute, direct toxic effect rather than a chronic vasculitic or hypoperfusion process [Discussion, penultimate paragraph].

With cardioembolism, atherosclerosis, and vasculitis all excluded, and given the absence of any traditional stroke risk factors, the authors conclude the most plausible mechanism is diffuse thrombotic microangiopathy induced by procoagulant venom components — the same VICC process already driving the patient's bleeding diathesis, here manifesting as widespread microthrombosis instead [Discussion, final two paragraphs], consistent with a small existing literature of similar cerebral-infarction cases after Russell's viper and other viper bites [Discussion, citing refs. 6–9].

Every citation used above, carried forward from the uploaded paper's own bibliography (Yadav et al., 2025, Cureus 17(7): e87988, doi: 10.7759/cureus.87988):

1. [1] Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebite envenoming. Nat Rev Dis Primers. 2017, 3:10.1038/nrdp.2017.63.
2. [2] Chippaux JP. Snakebite envenomation turns again into a neglected tropical disease! J Venom Anim Toxins Incl Trop Dis. 2017, 23:10.1186/s40409-017-0127-6.
3. [3] Suraweera W, Warrell D, Whitaker R, et al. Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study. Elife. 2020, 9:10.7554/eLife.54076.
4. [4] Seifert SA, Armitage JO, Sanchez EE. Snake envenomation. N Engl J Med. 2022, 386:68-78. 10.1056/NEJMra2105228.
5. [5] Warrell DA. Snake bite. Lancet. 2010, 375:77-88. 10.1016/S0140-6736(09)61754-2.
6. [6] Narang SK, Paleti S, Asad MA, Samina T. Acute ischemic infarct in the middle cerebral artery territory following a Russell's viper bite. Neurol India. 2009, 57:479-80. 10.4103/0028-3886.55594.
7. [7] Subasinghe CJ, Sarathchandra C, Kandeepan T, Kulatunga A. Bilateral blindness following Russell's viper bite - a rare clinical presentation: a case report. J Med Case Rep. 2014, 8: 10.1186/1752-1947-8-99.
8. [8] Murthy JM, Kishore LT, Naidu KS. Case report, cerebral infarction after envenomation by viper. J Comput Assist Tomogr. 1997, 21.
9. [9] Pothukuchi VK, Kumar A, Teja C, Verma A. A rare case series of ischemic stroke following Russell's viper snake bite in India. Acta Med Indones. 2018, 49.
10. [10] Noutsos T, Currie BJ, Wijewickrama ES, Isbister GK. Snakebite associated thrombotic microangiopathy and recommendations for clinical practice. Toxins (Basel). 2022, 14:10.3390/toxins14010057.
11. [11] Kularatne SA. Epidemiology and clinical picture of the Russell's viper (Daboia russelii russelii) bite in Anuradhapura, Sri Lanka: a prospective study of 336 patients. Southeast Asian J Trop Med Public Health. 2003, 34:855-62.
12. [12] Silva A, Maduwage K, Sedgwick M, et al. Neurotoxicity in Russell's viper (Daboia russelii) envenoming in Sri Lanka: a clinical and neurophysiological study. Clin Toxicol (Phila). 2016, 54:411-9. 10.3109/15563650.2016.1143556.
13. [13] Al-Sadawi M, Mohamadpour M, Zhyvotovska A, Ahmed T, Schechter J, Soliman Y, McFarlane SI. Cerebrovascular accident and snake envenomation: a scoping study. Int J Clin Res Trials. 2019, 4:10.15544/2456-8007/2019/133.

1 unit of analysis (the patient), with 7 checkpoint nodes on the confirmed path reconstructed from the Case Report section, plus 3 pruned-branch nodes from the Investigations/Discussion sections: Unwitnessed bite (delayed recognition), Acute neurotoxic crisis, ASV (20 vials) + ventilatory support, Acute discharge (no focal deficit), Delayed extrapyramidal onset (hub), MRI/CSF workup — leukoencephalopathy (hub) (with viral, hypoxic, and metabolic branches pruned here — see below), and Levodopa-carbidopa / disposition. Every value below is taken directly from the paper's Case Report section — no figures were estimated.

Hub / turning-point nodes

The Delayed extrapyramidal onset node (3 days after an already-completed hospital discharge) is the first turning point — the patient had been discharged "in stable, conscious, and oriented condition with no focal neurological deficits" before tremor and gait impairment appeared [Case Report, para. 2]. The MRI/CSF workup node is the second and central hub: this is where the paper's defining finding (bilateral caudate/globus pallidus/putamen T2/FLAIR change) was identified and where viral, hypoxic, and metabolic alternatives were actively excluded on the same node before the leukoencephalopathy-with-parkinsonism attribution was reached [Case Report, para. 3].

The paper's own Case Report is the textbook path for this case: a severe neurotoxic envenomation (ptosis, bulbar weakness, quadriparesis, respiratory failure) fully treated with ASV and extubated by day 3, followed by an entirely separate, delayed extrapyramidal syndrome that emerged only after the patient was ambulatory and had gone home, and that responded to levodopa-carbidopa once diagnosed [Case Report, paras. 1–4].

Sources: Case Report section; Figure 1 (handwriting/micrographia assessment); Figure 2 (MRI).

Three branch-points are the most informative divergences at this single-patient trajectory's central hub — each an alternative cause the workup actively tested for and excluded before attributing the parkinsonism to venom/ASV-related leukoencephalopathy:

1. Viral encephalitis branch — pruned by CSF/serum virology

CSF examination was normal, and the CSF and serum virology panel was negative for dengue, Japanese encephalitis, and herpes simplex, among others [Case Report, para. 3] — directly excluding an infectious encephalitic cause for the basal-ganglia signal change.

2. Hypoxic encephalopathy branch — pruned by absence of documented hypoxic insult

No metabolic derangements or hypoxic insults were documented during the hospital stay [Case Report, para. 4], ruling out the well-recognized alternative explanation for bilateral basal-ganglia/globus pallidus injury after a critical-illness ICU course.

3. Metabolic derangement branch — pruned by normal baseline and routine labs

Routine biochemical investigations at the delayed presentation were within normal limits, and baseline investigations from the earlier snakebite admission were also within normal limits [Case Report, paras. 3–4], excluding a metabolic driver for either the acute or delayed clinical picture.

With viral, hypoxic, and metabolic causes excluded on the same node, the authors attribute the leukoencephalopathy to the venom's endothelial-dysfunction mechanism — or, alternatively, to a delayed immune-mediated reaction to ASV itself, mirroring the mechanism proposed for other post-snakebite leukoencephalopathy/ADEM reports in their Discussion — without being able to distinguish between the two on this patient's data alone [Discussion, paragraphs on leukoencephalopathy mechanism].

Every citation used above, carried forward from the uploaded paper's own bibliography (Verma R, Prabhu V, Bal KP. Parkinsonism associated with snakebite. Ann Afr Med 2024;23:518–22, doi: 10.4103/aam.aam_151_23):

1. [1] Huang YK, Chen YC, Liu CC, Cheng HC, Tu AT, Chang KC. Cerebral complications of snakebite envenoming: Case studies. Toxins (Basel) 2022;14:436.
2. [2] Chaudhary SC, Sawlani KK, Malhotra HS, Singh J. Snake bite-induced leucoencephalopathy. BMJ Case Rep 2013;2013:bcr2012007515.
3. [3] Xu A, Shan R, Huang D, Zhou J, Keenoo A, Qin J. Case report: Acute demyelinating encephalomyelitis following viper bite. Medicine (Baltimore) 2016;95:e5310.
4. [4] Verma S, Resident S. Rare case of snake bite induced leucoencephalopathy. Int J Med Sci Curr Res 2018;1:1-4.
5. [5] ChandraSR, IssacTG, Gupta N. Snakebite, antivenom and mitochondrial toxicity. Annals of Medical and Health Sciences Research. 2017;7(3).
6. [6] Baineni R, Mallavarapu R, Devarapalli B, Ramarao V. Hypertensive encephalopathy with locked-in syndrome mimicking brain death: An unusual case of Krait envenomation with literature review. Asia Pac J Med Toxicol 2020;9:159-62.
7. [7] Ranawaka UK, Lalloo DG, de Silva HJ. Neurotoxicity in snakebite – The limits of our knowledge. PLoS Negl Trop Dis 2013;7:e2302.
8. [8] Delgado ME, Del Brutto OH. Reversible posterior leukoencephalopathy in a venomous snake (Bothrops asper) bite victim. Am J Trop Med Hyg 2012;86:496-8.
9. [9] Waiddyanatha S, Silva A, Siribaddana S, Isbister GK. Long-term effects of snake envenoming. Toxins (Basel) 2019;11:193.
10. [10] Malhotra P, Sharma N, Awasthi A, Vasishta RK. Fatal acute disseminated encephalomyelitis following treated snake bite in India. Emerg Med J 2005;22:308-9.
11. [11] Ramcharan K, Abdool K, Persad N, Alexander A. Snake bite-induced myoclonus, myokymia and myospasm with leukoencephalopathy: A video presentation. BMJ Case Rep 2016;2016:bcr2016214963.
12. [12] Sailaja K, Thomas SR, Reddy DR. Case report acute disseminated encephalomyelitis: A rare complication of snake bite. J Basic Clin Res 2015;2:30-2.
13. [13] Tripathy S, Routray PK, Mohapatra AK, Mohapatra M, Dash SC. Acute demyelinating encephalomyelitis after anti-venom therapy in Russell's viper bite. J Med Toxicol 2010;6:318-21.
14. [14] Chandna DP, Duhan DA, Malik DA, Yadav DR, Narayanan DN, Vasudha. MRI imaging of snake bite induced leukoencephalopathy. Int J Med Sci 2019;6:4-7.

5 units of analysis (the five VENOMS-registry patients), each with 6 checkpoint nodes reconstructed from the paper's own Case 3.1–3.5 narratives and Tables 1–2: Presentation, Peripheral-centre ASV ± reaction, Referral, Definitive-centre ASV/escalation, Complication, and Disposition. Every value below is taken directly from the paper's case narratives and Tables 1 and 2 — no figures were estimated.

Hub nodes

Peripheral-centre ASV ± reaction and Definitive-centre ASV/escalation are the series' two true hubs — all five patients received ASV at a peripheral centre first (doses 5–25 vials, undocumented brand) and all five received further ASV at the authors' own centre, with the total cumulative dose across the series averaging 31 vials (minimum 20, maximum 46) against a national-guideline initial dose of 5 vials [Discussion, para. 6].

Checkpoints that turned out to be outlier-only

Complication is where the five trajectories fork hardest: three patients (Cases 1, 3, 5) developed anaphylaxis to ASV requiring antihistamine/hydrocortisone, two of whom (Cases 1, 5) needed a continuous inotrope infusion [Table 2; Discussion, para. 6]; Case 4 is the series' persistent-VICC outlier, presenting with severe coagulopathy on day 7 despite 25 vials of ASV already given at the peripheral centre [Abstract; Case 3.4].

Three of five patients (Cases 1–3) follow the series' modal shape: local envenomation ± bleeding manifestation, ASV at a peripheral centre, an early reaction to that ASV, transfer, further ASV at the authors' centre for persisting coagulopathy, and full recovery by day 3–5. All five ultimately converge on the same "recovered, no residual disability" disposition node despite widely varying severity and vial counts [Discussion, para. 7].

Sources: Case Details 3.1–3.3; Tables 1–2.

Case 4 (30M) — day-7 transfer, VICC unresponsive to 25 peripheral vials

Case 4 sought Ayurvedic care first, was then admitted to a local hospital within 1.5 hours of the bite, and received 25 vials of ASV, 20 units of FFP, and 4 units of cryoprecipitate there — yet arrived at the authors' centre on day 7 with persistent coagulopathy, haematuria, and abdominal pain, D-dimer >10 mcg/mL, requiring a further 10 vials of ASV, tranexamic acid, and 1 unit PRBC before improving and being discharged after a further 7 days [Case 3.4]. The authors flag this case by name as evidence that "recommended and timely initial dosing of ASV at the primary care level does not appear to have prevented or corrected VICC" [Discussion, para. 8].

Case 5 (49M, HIV+) — highest cumulative ASV (46 vials), altered sensorium, seizure-like event

Case 5, a known case of retroviral disease on ART with old pulmonary tuberculosis and INH-induced peripheral neuropathy, developed altered sensorium, a seizure-like event, and bleeding from the oral cavity with tongue haematoma (GCS E2V1M5); TEG suggested VICC, CK was 1192 U/L, LDH 412 U/L, and troponin T 0.209 ng/mL. He received the series' highest cumulative ASV dose — 5 vials peripherally, then 10, then 20, then 11 more vials over the following two days (46 total) — plus a noradrenaline infusion, before CT/MRI brain (both normal) and full recovery by day 4 [Case 3.5]. The authors note "a dearth of literature of the interaction of snake venom and HIV" for this presentation [Discussion, para. 7].

Read together, Cases 4 and 5 anchor the paper's central argument: across the series, cumulative ASV dosing (20–46 vials, mean 31) ran far above the national/WHO-SEARO initial-dose recommendation of 4–6 vials, yet complications — including anaphylaxis in three of five patients and VICC unresponsive to early adequate dosing in Case 4 — occurred regardless, which the authors attribute to regional venom-composition variation not covered by the current ASV venom pool [Discussion, paras. 1–2, 8–9].

Every citation used above, carried forward from the uploaded paper's own bibliography (Lath V, Shekhawat D, Sirur FM. Strikes and stripes of the Saw-scaled Viper in the Western Ghats-A case series. Toxicol Rep 2024;13:101721, doi: 10.1016/j.toxrep.2024.101721):

1. [1] Gutiérrez JM, Maduwage K, Iliyasu G, Habib A. Snakebite envenoming in different national contexts: Costa Rica, Sri Lanka, and Nigeria. Toxicon X 2021;9-10:100066.
2. [2] Pitman CRS. The saw-scaled viper (B carpet viper, Echis carinatus) in africa and its bite. J Herpetol Assoc Afr 1972;9(1):6-34.
3. [3] Kochar DK, Tanwar PD, Norris RL, et al. Rediscovery of severe saw-scaled viper (Echis sochureki) envenoming in the Thar Desert Region of Rajasthan, India. Wilderness Environ Med 2007;18(2):75-85.
4. [4] Fonseka CL, Jeevagan V, Gnanathasan CA. Life threatening intracerebral haemorrhage following saw-scaled viper (Echis carinatus) envenoming — authenticated case report from Sri Lanka. BMC Emerg Med 2013;13(1).
5. [5] Kumar A, Gopalakrishnan M, Kuri HR, Bajpayee A, Kothari N, Garg MK. Case Report: delayed diffuse alveolar hemorrhage in Echis sochureki envenoming, Jodhpur, India. Am J Trop Med Hyg 2022;106(3):967-9.
6. [6] Rathod S, Dhar A. Saw scaled viper bite and envenomation in the subcutaneous plane. J Fam Med Prim Care 2023;12(2):413.
7. [7] Pirasath S, Athirayan C, Gajan D. Thrombotic microangiopathy following saw-scaled viper (Echis carinatus) envenoming in Sri Lanka. SAGE Open Med Case Rep 2021;9.
8. [8] Obeidat MB, Al-Swailmeen AM, Al-Sarayreh MM, Rahahleh KM. Thrombotic microangiopathy following arabian saw-scaled viper (Echis coloratus) bite: case report. Am J Case Rep 2020;21.
9. [9] Gopal G, Selvaraj H, Venkataramanan SK, et al. Systematic review and meta-analysis on the efficacy of Indian polyvalent antivenom against the Indian snakes of clinical significance. Arch Toxicol 2024;98(2):375-93.
10. [10] Bhatia S, Vasudevan K. Comparative proteomics of geographically distinct saw-scaled viper (Echis carinatus) venoms from India. Toxicon X 2020;7.
11. [11] Guidelines for the Management of Snakebites, 2nd edition. World Health Organization Regional Office for South-East Asia, 2016.
12. [12] Standard Treatment Guidelines — Management of Snake Bite. Ministry of Health & Family Welfare, Government of India, 2016.
13. [18] Bhatia S, Vasudevan K. Comparative proteomics of geographically distinct saw-scaled viper (Echis carinatus) venoms from India. Toxicon X 2020;7.
14. [19] Gopalakrishnan M, Yadav P, Mathur R, Midha N, Garg MK. Venom-induced consumption coagulopathy unresponsive to antivenom after echis Carinatus sochureki envenoming. Wilderness Environ Med 2021;32(2):221-5.
15. [20] Patra A, Kalita B, Chanda A, Mukherjee AK. Proteomics and antivenomics of Echis carinatus carinatus venom: Correlation with pharmacological properties and pathophysiology of envenomation. Sci Rep 2017;7(1):17119.
16. [21] Bhatia S, Blotra A, Vasudevan K. Evaluating Antivenom efficacy against Echis carinatus Venoms—Screening for In Vitro Alternatives. Toxins (Basel) 2022;14(7):481.
17. [22] Firth GB, Street M, Ramguthy Y, Doedens L. Mortality following snake bite envenomation by Bitis arietans in an HIV positive child. Medicine 2016;95(27):e4001.
18. [23] Menon JC, Joseph JK, Jose MP, et al. Management protocol of venomous snakebite in India: a consensus statement. Toxin Rev 2016;35(3-4):147-51.
19. [24] Gnanathasan A, Rodrigo C, Peranantharajah T, Coonghe A. Case report: Saw-scaled viper bites in Sri Lanka: Is it a different subspecies? Clinical evidence from an authenticated case series. Am J Trop Med Hyg 2012;86(2):254-7.
20. [25] de Silva HA, Ryan NM, de Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment. Br J Clin Pharm 2016;81(3):446-52.

1 unit of analysis (the patient), with 7 checkpoint nodes on the confirmed path reconstructed from the Case Report and Table 1 timeline, plus 1 pruned-branch node from the Introduction/Discussion: Bite + local care, Local-centre ASV escalation (35 vials), Tertiary arrival (~24h, paradoxical no-bleed-on-prick), Referral diagnosis: DIC (pruned), Definitive-centre ASV/blood-product escalation (hub, total 65 vials), Multiorgan deterioration (hub), Death, and Autopsy — confirmed VICC+TMA. Every value below is taken directly from the paper's Case Report section and Table 1.

Hub / turning-point nodes

The Definitive-centre escalation node (total 65 vials ASV across 3 centres, plus 2 units PRBC, 6 units random-donor platelets, 6 units FFP, 10 units cryoprecipitate) is the trajectory's first hub — the paper explicitly uses this dose to argue that ASV inefficacy, not under-dosing, explains the non-response [Discussion, "the possibility of poor efficacy of ASV is highly unlikely"]. The Multiorgan deterioration node (anuria, ARDS, mechanical ventilation, CVVHD) is the second hub — the point from which the patient did not recover, 12 hours after ICU escalation [Case Report, final paragraph].

The paper's own Case Report and Table 1 timeline form the textbook path for this case: a right-ankle SSV bite treated with early but escalating ASV at three separate centres, arriving disoriented and swollen but paradoxically not bleeding on pinprick despite severe coagulopathy, deteriorating into anuria and ARDS despite 65 vials of ASV and multiple blood-product transfusions, and dying approximately 60 hours post-bite — with autopsy confirming the paper's central VICC+TMA re-diagnosis [Case Report; Discussion].

Sources: Case Report section; Table 1; Figs. 1–3 (autopsy histology).

Referral diagnosis: DIC — pruned on clinical grounds, then autopsy

The patient arrived at the authors' tertiary centre already labeled a case of DIC. The authors reclassify this in real time based on the clinical picture — hemolysis (schistocytes, indirect hyperbilirubinemia, raised LDH), thrombocytopenia, non-focal altered sensorium with normal brain parenchyma, and glomerular capillary thrombi without mesangiolysis or large-vessel involvement — arguing this pattern fits VICC coexisting with TMA rather than DIC, since DIC is tissue-factor driven, later in onset, and histologically shows mesangiolysis [Case Report, penultimate paragraph; Discussion, "multiple features differentiate DIC from VICC"]. A second, related clue the authors cite: the patient was not bleeding on capillary fingerprick despite severely deranged coagulation parameters — a pattern the authors note is inconsistent with the systemic microthrombi/consumptive bleeding tendency of true DIC and more in keeping with localized microvascular (TMA) thrombosis [Case Report, third paragraph].

The autopsy — fibrin microthrombi in glomerular and lung capillaries without mesangiolysis, normal main/segmental renal arteries, and concurrent acute tubular necrosis with myoglobin casts (rhabdomyolysis) — is presented as confirmation of the VICC+TMA reclassification rather than DIC [Discussion, "pathological findings were in agreement with our clinical diagnosis of TMA with VICC"]. The authors separately argue that the persistence of coagulopathy despite 65 vials of ASV (well above the "not more than 20 to 30 vials" usually needed) makes poor ASV efficacy against E. carinatus sochureki — a subspecies whose venom is not represented in the Tamil Nadu-sourced Indian polyvalent ASV — a more likely explanation than under-treatment [Discussion, penultimate paragraph].

Every citation used above, carried forward from the uploaded paper's own bibliography (Prakash S, Vikram A, Kashif AW, Khare S. Sochureki, the different saw-scaled viper: Challenges are many! Med J Armed Forces India 2025;81:99–104, doi: 10.1016/j.mjafi.2023.11.004):

1. [1] World Health Organization: Snakebite envenoming. Available from: https://www.who.int/news-room/ fact-sheets/detail/snakebite-envenoming, accessed February 23, 2020.
2. [2] Suraweera W, Warrell D, Whitaker R, et al. Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study. Elife 2020;9:e54076.
3. [3] Mohapatra B, Warrell DA, Suraweera W, et al. Snakebite mortality in India. A Nationally representative mortality. 2011;5:e1018.
4. [4] Central Bureau of Health Intelligence. National health profile; 2019:151-152.
5. [5] Chakma Joy K, Jaideep C, Menon RS, Dhaliwal, Indian council of medical research. White paper on venomous snakebite in India. Indian J Med Res 2020;152:568-574.
6. [6] Saw-scaled Viper, Sochureki's or Eastern Saw-scaled viper, Multiscale or Transcaspian Saw-scaled viper, Astola Saw-scaled viper [Internet] 2003.
7. [7] Pirasath S, Athirayan C, Gajan D. Thrombotic microangiopathy following saw-scaled viper (Echis carinatus) envenoming in Sri Lanka. SAGE Open Med Case Rep 2021;9.
8. [8] Isbister GK. Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost 2010;36(4):444-451.
9. [9] Cortelazzo A, Guerranti R, Bini L, et al. Effects of snake venom proteases on human fibrinogen chains. Blood Transfus 2010;8(suppl 3):s115-s120.
10. [10] Paliwal G, Prakash S, Kashif AW. Renal and hepatic changes in a case of envenomation by snake bite: case report and review of literature. Indian J Pathol Microbiol 2022;65(4):934-937.
11. [11] Whitaker R, Whitaker S. Venom, antivenom production and the medically important snakes of India. Curr Sci 2012;103:635-643.
12. [12] Jia X, He Y, Ruan CG. [Research advances of acquired thrombotic thrombocytopenic purpura — review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018;26(4):1230-1234.
13. [13] Moujahid A, Laoutid J, Hajbi H, et al. Plasma exchange therapy in a severe snake bite victim. Ann Fr Anesth Reanim 2009;28(3):258-260.

Two extraction layers, per Module E: (1) CONSORT flow — assessed for eligibility 52 → excluded 2 (1 severe diabetes, 1 renal insufficiency) → randomized 50 → allocated 25/25 → received allocated intervention 25/25 (zero dropouts reported) → analyzed 25/25 [§2.2.1(2); Fig 1 CONSORT diagram]. (2) Arm-level trajectory nodes (no per-patient data reported): Baseline (Table 2 — age, height, weight, BMI, bite site, time-to-treatment, snake length, severity score; no significant between-arm difference on any variable, all p>0.05) [Table 2], Allocation/intervention-delivery (both arms: IV Naja naja/atra antivenin + tetanus antitoxin + wound rinse + dexamethasone + 2nd-gen cephalosporin as base; local-closure solution differs by arm — Table 1 dosing by body part) [§2.3.1–2.3.2; Table 1], Adverse-event node (2/50 patients, 4%, had a sparse-rash reaction to IV ASV; infusion slowed 2→0.5 U/min, dexamethasone increased — arm not individually specified) [§3.2], Outcome-assessment node (necrosis volume Day 1/3/7, Table 3; wound-healing time, Fig 2; pathology, Figs 3–4) [§3.3–3.6].

Hub nodes

Every one of the 50 randomized patients passes through the same five checkpoints in the same order (Baseline → Allocation → Local closure → Day-3 assessment → Day-7/disposition) — there is no attrition edge-thinning anywhere in this trial (0 dropouts, 0 deaths), so hub weight is uniform across both arms rather than concentrated at one node, unlike the case-report corpus above.

Sources: Table 1–3; Fig 2–4; §3.1–3.6.

Primary divergence — Day-3 necrosis volume

The trial's clearest divergence point is the Day-3 necrosis-volume assessment: both arms start statistically indistinguishable on Day 1, but by Day 3 the control arm's necrotic volume has jumped roughly 23-fold higher than the experimental arm's (1674.44±972.35 mm³ vs 71.16±41.56 mm³, p<0.05), and the paper's own explanation is that chymotrypsin has "a relatively weak destructive effect on snake venom protein" despite being a proteolytic enzyme, while local ASV — a specific antibody — neutralizes cytotoxin directly at the wound site [§4, para. 8].

Flagged anomaly — Day-7 control-arm variance

OUTLIER (data-quality flag, not clinical divergence): the paper's own Table 3 reports the Day-7 control-group necrosis volume as 172.68 ± 901.06 mm³ — a standard deviation more than 5× the mean, which is numerically implausible for a strictly non-negative volume measure and is carried here exactly as printed in the source table rather than corrected or estimated [Table 3]. This is flagged rather than silently smoothed, per the module's constraint against inventing or adjusting reported values.

Secondary point — adverse events not arm-attributed

The only adverse-event node in the trial (2/50 IV-ASV rash reactions, 4% incidence) is reported at the whole-cohort level, not broken out by arm [§3.2], so it cannot be placed on one arm's path specifically — shown here as a shared cohort-level checkpoint rather than assigned to either textbook path.

Every citation used above, carried forward from the uploaded paper's own bibliography (Zeng et al., 2022, PLOS Neglected Tropical Diseases 16(12): e0010997):

1. [1] Seifert SA, Armitage JO, Sanchez EE. Snake Envenomation. N Engl J Med. 2022; 386:68–78.
2. [13] Liu CC, Chou YS, Chen CY, Liu KL, Chen CK. Pathogenesis of local necrosis induced by Naja atra venom: Assessment of the neutralization ability of Taiwanese freeze-dried neurotoxic antivenom in animal models. PLOS Negl Trop Dis. 2020; 14:e8054.
3. [18] Hsieh YH, Hsueh JH, Liu WC, Yang KC, Hsu KC, Lin CT, et al. Contributing Factors for Complications and Outcomes in Patients With Snakebite. Ann Plast Surg. 2017; 78:S32–6.
4. [19] Mao YC, Liu PY, Chiang LC, Lai CS, Ho KL, Wang CH, et al. Naja atra snakebite in Taiwan. Clin Toxicol (Phila). 2018; 56:273–80.
5. [20] Z H. Study on the rationality of local blocking of chymotrypsin injection in the treatment of Chinese cobra bite envenoming. Guangxi Medical University. 2016.
6. [21] Shah D, Mital K. The Role of Trypsin: Chymotrypsin in Tissue Repair. Adv Ther. 2018; 35:31–42.
7. [22] Li QB, Li CZ, Liang ZJ, Zhang JF, Wang W, RD L. Consensus of Chinese snake wound treatment experts in 2018. Snake records. 2018; 30:561–7.
8. [38] Yeh H, Gao SY, Lin CC. Wound Infections from Taiwan Cobra (Naja atra) Bites. Toxins. 2021; 13.
9. [48] de Silva HA, Ryan NM, de Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment. Br J Clin Pharmacol. 2016; 81:446–52.

Two extraction layers, per Module E: (1) CONSORT-style flow — 94 volunteers met inclusion/exclusion criteria and were randomized → assigned to 8 single-dose groups (n=64: 2,2,10,10,10,10,10,10 for 0.33, 0.66, 1, 1.5, 2, 3, 4, 5 µg/60kg) or 3 loading-dose+CRI groups (n=30: 6, 12, 12 for 3 µg/60kg+CRI-at-1.5h, 3 µg/60kg+CRI, 5 µg/60kg+CRI) → 93 analyzed (1 dropped out prior to the trial for personal reasons — the paper does not report a separate pre-randomization screening/exclusion count, unlike Case 13's 52→50 funnel) [Fig 4; Methods §Study design; §Phase I clinical trial protocol]. (2) Arm-level trajectory nodes (no per-patient PD/safety data reported): Baseline (dose/ regimen allocation, Fig 4), Administration (single 5-min IV bolus, or bolus + 0.12 µg/60kg/h CRI for 24h) [§Drug administration and tolerance test], PD-peak node (Emax, Tmax — maximal ristocetin-aggregation inhibition and time to reach it, Table 1) [Table 1; Fig 6], Safety-monitoring node (platelet count pre/post, Table 2; PT/TT/aPTT/INR/D-dimer, Fig 7; bleeding time, Fig 8 — no significant change on any parameter, any dose) [Table 2; Figs 7–8], Disposition node (Tmin — time effect returns to near-baseline; 0 SAEs; 0 anti-anfibatide antibodies; no thrombocytopenia) [Table 1; §Safety and adverse events].

Hub nodes

All 93 analyzed subjects pass through the same five checkpoints in the same order with no attrition edge-thinning after randomization (0 dropouts during the trial itself; the single dropout occurred before dosing) — hub weight is therefore uniform across all 11 arms, as in Case 13, but here the interesting structure is not attrition, it's the dose gradient itself: Emax and AUEC climb monotonically with dose from the lowest tabulated single-dose arm (1 µg/60kg) to the highest (4–5 µg/60kg), then plateau.

Sources: Table 1; Table 2; Figs 5–8.

Primary divergence — dose-dependent Emax plateau vs. CRI-extended duration

Two distinct "divergence" structures sit side by side in this trial: within the single-dose arms, Emax rises with dose and plateaus near 97–98% by 4 µg/60kg with no further gain at 5 µg/60kg, while Tmin (time to effect resolution) keeps stretching out to a flat 8.0±0.0h ceiling at both 4 and 5 µg/60kg — i.e. higher single doses buy longer duration more than they buy extra peak effect past ~4 µg/60kg. The CRI arms diverge from this pattern entirely: sustained infusion holds Emax at a lower, steadier 81–95% for the full 24h infusion, then the effect resolves rapidly (within ~4h of stopping infusion, Fig 6B) rather than gradually — the two dosing strategies produce different shapes of the same pharmacodynamic curve, not just different magnitudes [Table 1; Fig 6A–B].

Flagged anomaly — in vivo potency ~1000× higher than in vitro

OUTLIER (unresolved mechanism, flagged by the paper's own authors): anfibatide inhibited ristocetin-induced platelet aggregation in these volunteers at doses as low as 1 µg/60kg, while the paper's own in vitro SPR/binding data report K_D/K_i values in the low-nanomolar range requiring far higher concentrations to saturate — the authors explicitly flag that the in vivo effect "seems to be far more potent than in vitro assays… several thousand times less" and note this "deserves further investigation" rather than offering a settled explanation [Discussion, para. 2; Abstract]. This is carried here exactly as the paper frames it — an open question, not resolved by this study.

Secondary point — small-N safety-only arms excluded from the PD table

Groups 1 and 2 (0.33 and 0.66 µg/60kg, n=2 each) were dosed and safety-monitored (Table 2 reports their platelet counts) but do not appear in the pharmacodynamic Emax/Tmax/Tmin/AUEC table (Table 1) — the paper does not state why, but the n=2 size and their placement as the lowest Fibonacci-escalation steps suggests they served a pure tolerability-finding role before the trial's PD-bearing dose range began at 1 µg/60kg [Fig 4; Table 1 vs. Table 2 comparison]. This granularity gap is noted rather than papered over.

Every citation used above, carried forward from the uploaded paper's own bibliography (Li et al., 2021, Scientific Reports 11:11663):

1. [6] Bergmeier, W. et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 103, 16900–16905 (2006).
2. [21] Lei, X. et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 111, 279–289 (2014).
3. [24] Gao, Y. et al. Crystal structure of agkisacucetin, a GPIb-binding snake C-type lectin that inhibits platelet adhesion and aggregation. Proteins 80, 1707–1711 (2012).
4. [28] Li, J. et al. Platelet protein disulfide isomerase promotes glycoprotein Ibalpha-mediated platelet-neutrophil interactions under thromboinflammatory conditions. Circulation (2018).
5. [35] Hou, Y. et al. The first in vitro and in vivo assessment of anfibatide, a novel glycoprotein Ib antagonist, in mice and in a phase I human clinical trial. Blood 122, 577–577 (2013).
6. [41] Zheng, L. et al. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura. Blood Adv 1, 75–83 (2016).
7. [46] Zarpellon, A. et al. Binding of alpha-thrombin to surface-anchored platelet glycoprotein Ib(alpha) sulfotyrosines through a two-site mechanism involving exosite I. Proc Natl Acad Sci USA 108, 8628–8633 (2011).
8. [58] Gilbert, J. C. et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116, 2678–2686 (2007).
9. [60] Peyvandi, F. et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374, 511–522 (2016).
10. [75] Anfibatide Phase 1 Clinical Trial in Healthy Volunteers; NCT01588132, submitted 2012 Apr 25, posted 2012 Apr 30. clinicaltrials.gov/ct2/show/NCT01588132 (2012).

Per Module F, each included study is extracted as a 5-node chain: identification (author/year, design), population/setting (n, country, envenomation type), intervention definition (exact high- vs low-dose regimen), effect estimate (per pooled outcome, with RevMan weight %), and risk-of-bias (open-label vs. blinded) [Table 1; Table 2].

Hub nodes

Every included study shares the same top-level design node (RCT comparing a high- vs low-dose SAV regimen) and the same broad population frame (systemic envenomation, adjunct to standard hospital care) — this is the "typical included study" the review is built on. But the intervention-definition node is not a hub in the way population/design are: dose thresholds range from 20mL to 220mL for "low dose" and 40mL to 550mL for "high dose" across the 5 trials [Abstract; Table 1], meaning the studies share a comparison structure but not a shared operational definition of either arm — the review's own Discussion calls this "a jigsaw puzzle" [Discussion, para. 2].

The review's "textbook path" analog is this five-outcome pooled-estimate set: on every outcome the point estimate favors the low-dose group, but only duration of hospital stay reaches statistical significance [Fig 2–6; Table 3]. Every pooled estimate carries a GRADE rating of "very low quality," driven mainly by the open-label design of 3/5 included trials [Table 3; Limitations].

Divergence 1 — Jorge et al. 1995: narrowest population, different venom family

Jorge et al. is the only included trial conducted outside India, the only one using Bothrops (pit viper) envenomation in Brazil rather than the Indian subcontinent's cobra/krait/viper mix, and the only one that explicitly excluded severe envenomation, studying mild-to-moderate cases only [Table 1]. Despite this narrower population, its point estimate direction (low dose superior, less anaphylaxis risk) agrees with the pooled direction — but it is not itself pooled into any of the five forest plots (Figs 2–6), since its outcome set — CT normalization and 1-month follow-up clinical parameters — doesn't map onto the mortality/ARF/bleeding/stay outcomes the other four trials share [Results §Description of studies; Table 1]. This is a genuine outcome-definition mismatch, not a data-availability gap — flagged rather than force-pooled.

Divergence 2 — Srimannarayana et al. 2004: three-arm design collapsed to two

This trial is the only one of the five with three parallel regimens (high dose, low-regimen-I, low-regimen-II) rather than a simple two-arm comparison, and the only one that stratified dosing by envenomation severity from the outset [Table 1]. To fit the review's two-group forest-plot structure, its two low-dose arms were combined into a single "low dose" n=60 cell for pooling — the review does not report combining methodology in detail, so this is noted as a structural simplification rather than a reported study-level number [Table 1; Figs 2–6, Srimannarayana row].

Definitional-drift outlier — dose ranges span an 11-fold spread

OUTLIER (definitional heterogeneity, not a single study): "low dose" spans 20–220mL and "high dose" spans 40–550mL across the five trials — an overlap wide enough that some trials' "high dose" arm is numerically smaller than other trials' "low dose" arm [Abstract]. The review's own Discussion names this directly: the optimal dose schedule "remains a jigsaw puzzle considering the different low dose schedule defined in different trials" [Discussion, para. 2]. No single study is at fault here — this is a corpus-level definitional-drift outlier, the kind Module F is built to surface.

Publication-bias flag

The funnel plot (Fig 7, mortality outcome) is visually asymmetric, and the paper states plainly that "the possibility of publication bias cannot be ruled out" [Results §Publication bias] — carried here as the paper states it, not resolved or dismissed.

Every citation used above, carried forward from the uploaded paper's own bibliography (Das, Sankar & Dev, 2015, Indian Journal of Critical Care Medicine 19(6):340-349):

1. [1] Kasturiratne A, et al. The global burden of snakebite: A literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 2008; 5:e218.
2. [6] Tariang DD, Philip PJ, Alexander G, Macaden S, Jeyaseelan L, Peter JV, et al. Randomized controlled trial on the effective dose of anti-snake venom in cases of snake bite with systemic envenomation. J Assoc Physicians India 1999; 47:369-71.
3. [12] The Nordic Cochrane Centre. Review Manager (RevMan) 5.2. Copenhagen: The Cochrane Collaboration; 2012.
4. [13] Srimannarayana J, Dutta TK, Sahai A, Badrinath S. Rational use of anti-snake venom (ASV): Trial of various regimens in hemotoxic snake envenomation. J Assoc Physicians India 2004; 52:788-93.
5. [14] Paul V, Pratibha S, Prahlad KA, Earali J, Francis S, Lewis F. High-dose anti-snake venom versus low-dose anti-snake venom in the treatment of poisonous snake bites – A critical study. J Assoc Physicians India 2004; 52:14-7.
6. [15] Thomas PP, Jacob J. Randomised trial of antivenom in snake envenomation with prolonged clotting time. Br Med J (Clin Res Ed) 1985; 291:177-8.
7. [16] Jorge MT, Cardoso JL, Castro SC, Ribeiro L, França FO, de Almeida ME, et al. A randomized 'blinded' comparison of two doses of antivenom in the treatment of Bothrops envenoming in São Paulo, Brazil. Trans R Soc Trop Med Hyg 1995; 89:111-4.
8. [17] Isbister GK, Shahmy S, Mohamed F, Abeysinghe C, Karunathilake H, Ariaratnam A. A randomised controlled trial of two infusion rates to decrease reactions to antivenom. PLoS One 2012; 7:e38739. (Excluded — compared infusion rate, not dose.)
9. [18] Abubakar IS, et al. Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria. PLoS Negl Trop Dis 2010; 4:e767. (Excluded — compared antivenom preparations, not dose.)
10. [19] Pardal PP, et al. Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans R Soc Trop Med Hyg 2004; 98:28-42. (Excluded — compared antivenom preparations, not dose.)
11. [21] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
12. [22] Schünemann H, Brozek J, Oxman A, editors. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation, v3.2. 2008.

Per Module F, each included study is extracted as a 5-node chain: identification (first author/year, country, design), population/setting (study population denominator, snakebite case count, study period), outcome definition (whether the study reports total bites or envenomings, and over what denominator year), effect estimate (incidence and/or mortality per 100,000 population/year), and risk-of-bias (NOS good/fair/poor) [Table 1; Table 2; S1 Quality Assessment]. Because 65 primary studies is far too many to list individually as forest rows in one readable plot, this module surfaces the review's own continent-level subgroup pooled estimates (Table 3, incidence; Table 4, mortality) as the forest rows — each row is itself already a random-effects pool of several primary studies, exactly analogous to how Case 15 pools individual RCTs into outcome-level diamonds, just one tier further aggregated.

Hub nodes

Across the 65 studies, the shared "typical included study" profile is a cohort design (37/65), hospital-based or community-based setting, reporting a raw snakebite case count over a multi-year period, converted by the review authors to a rate using the country/catchment population for that year [Table 1; Methods §Outcome measure]. Demographically, the pooled population across studies is 58.9% male, 27.5% agricultural workers (of those reporting occupation), and 66.7% rural residents (of those reporting residence) — these are hub nodes in the population layer, not the outcome layer [Table 2]. The outcome-definition node is not a hub: studies mix "all snakebites" and "envenomings only" as numerators inconsistently, and the review itself flags that it cannot determine, especially in community surveys, whether "all bites" includes non-venomous and dry bites from venomous species [Discussion, para. 3].

The review's "textbook path" analog is this cross-stratified pooled-estimate set: on every stratification (continent, income, quality, study design, study setting), the point estimate for both incidence and mortality is highest in Asia and in lower-middle/low-income countries, and the paper's own central finding is precisely this disparity — reported incidence highest in lower-middle-income countries, but mortality burden highest in low-income countries [Abstract; Conclusion]. Unlike Case 15, none of these pooled estimates carries a formal GRADE certainty rating — the review reports NOS quality per study but does not GRADE the pooled estimates themselves.

Divergence 1 — four sensitivity-flagged studies drive >10% shifts in pooled incidence

Leave-one-out sensitivity analysis found the global pooled incidence (69.4/100k/yr) changed by more than 10% only when four specific studies were individually removed: Alcoba et al. 2020 (Cameroon, cross-sectional; removal → 58.9, 95%CI 31.8–86.1), Rahman et al. 2010 (Bangladesh; removal → 59.6, 95%CI 31.9–87.3), Ediriweera et al. 2021 (Sri Lanka; removal → 61.2, 95%CI 32.3–103.9), and Vongphoumy et al. 2015 (Laos, 2 studies; removal → 56.9, 95%CI 31.6–82.3) [Fig 6; Results §Sensitivity analysis]. All four are Asian community-survey studies with very high per-study incidence estimates (e.g., Vongphoumy 355.1–1104.9/100k/yr in the forest plot, Fig 2) — the paper does not resolve whether this reflects genuinely higher true incidence in these specific catchments or survey-methodology differences (active community case-finding vs. passive hospital reporting) [Fig 2; Discussion]. Notably, overall heterogeneity (I²) stayed at 100.0% even after removing each of these — meaning no single study, however influential on the point estimate, is "responsible for" the heterogeneity itself.

Divergence 2 — mortality sensitivity outliers: Gampini 2016 and Majumder 2014

For the mortality pooled estimate (0.33/100k/yr), only two studies shifted the pooled figure by >10% on removal: Gampini et al. 2016 (Burkina Faso; removal → 0.27, 95%CI 0.11–0.43) and Majumder et al. 2014 (West Bengal, India; removal → 0.21, 95%CI 0.09–0.32) [Fig 7; Results §Sensitivity analysis]. Majumder's own stated focus is underreporting of snakebite deaths — its inclusion pulls the pooled mortality rate up, consistent with the review's broader point that hospital-based studies systematically undercount deaths that occur before reaching care [Discussion, citing ref. 61].

Definitional-drift outlier — "all bites" vs. "envenomings" numerator inconsistency

OUTLIER (definitional heterogeneity, not a single study): across the 65 studies, 57.3% of the 49,920 cases with snake-type data were confirmed venomous-snake bites, but previous literature the review cites found envenoming proportions ranging from 12% to 87% of all bites [Results; Discussion, citing ref. 6] — meaning some included studies' "incidence" numerator counts any bite, others count only confirmed envenomings, and this is not adjustable after the fact. Unlike Case 15, where the review names this drift directly in its Discussion as a "jigsaw puzzle," this review names it as a fundamental data-availability limitation rather than resolving it [Discussion, para. 4].

Unexplained-heterogeneity flag

I² exceeded 75% ("substantial heterogeneity") for both incidence and mortality across every single stratification tested (continent, income, study design, study setting, study quality) — the review states explicitly that none of these stratifications could identify the studies primarily responsible for the heterogeneity [Results §Meta-analysis of incidence and mortality]. This is carried here as the paper states it — an acknowledged, unresolved heterogeneity ceiling, not something this module can resolve by re-slicing the data further.

Every citation used above, carried forward from the uploaded paper's own bibliography (Afroz A, Siddiquea BN, Chowdhury HA, Jackson TNW, Watt AD. Snakebite envenoming: A systematic review and meta-analysis of global morbidity and mortality. PLoS Negl Trop Dis 2024; 18(4):e0012080):

1. [6] Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 2008; 5(11):e218.
2. [20] Alcoba G, Chabloz M, Eyong J, Wanda F, Ochoa C, Comte E, et al. Snakebite epidemiology and health-seeking behavior in Akonolinga health district, Cameroon: cross-sectional study. PLoS Negl Trop Dis 2020; 14(6):e0008334.
3. [39] Ediriweera DS, Kasthuriratne A, Pathmeswaran A, Gunawardene NK, Jayamanne SF, Murray K, et al. Evaluating spatiotemporal dynamics of snakebite in Sri Lanka: Monthly incidence mapping from a national representative survey sample. PLoS Negl Trop Dis 2021; 15(6):e0009447.
4. [43] Gampini S, Nassouri S, Chippaux J-P, Semde R. Retrospective study on the incidence of envenomation and accessibility to antivenom in Burkina Faso. J Venom Anim Toxins Incl Trop Dis 2016;22.
5. [61] Majumder D, Sinha A, Bhattacharya SK, Ram R, Dasgupta U, Ram A. Epidemiological profile of snake bite in south 24 Parganas district of West Bengal with focus on underreporting of snake bite deaths. Indian J Public Health 2014; 58(1):17-21.
6. [69] Rahman R, Faiz MA, Selim S, Rahman B, Basher A, Jones A, et al. Annual incidence of snake bite in rural Bangladesh. PLoS Negl Trop Dis 2010; 4(10):e860.
7. [79] Vongphoumy I, Phongmany P, Sydala S, Prasith N, Reintjes R, Blessmann J. Snakebites in two rural districts in Lao PDR: community-based surveys disclose high incidence of an invisible public health problem. PLoS Negl Trop Dis 2015; 9(6):e0003887.
8. [91] Abbafati C, Machado D, Cislaghi B, Salman O, Karanikolos M, McKee M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258):1204-22.

Per Module F, each included study is extracted as a 5-node chain: identification (author/year, design, country), population/setting (n, snake species, envenomation-to-ASV time), intervention definition (FFP dose/timing relative to ASV), effect estimate (per-outcome OR with RevMan weight %), and risk-of-bias (RoB2 domains for RCTs, NOS stars for cohorts) [Table 1; Figs 5-6; Table 4].

Hub nodes

All four studies share the same top-level design node (adjunctive FFP vs. ASV-alone for hemotoxic snakebite coagulopathy) and the same broad intervention timing (FFP given <4h after first ASV administration in three of four studies) [Table 1] — this is the "typical included study" hub. But the outcome-assessment node is not a hub: three studies use INR<2 while Holla 2018 uses 20-minute whole blood clotting time (20WBCT)<20min, and even among the INR-based studies the assessment timing ranges from 6h to 4-9h after the first ASV dose [Table 1]. The snake-species node is also not a hub: Isbister 2009/2013 study Australian elapids (brown snakes, tiger snakes, taipans, which contain prothrombin activators), while Isbister 2017 studies Sri Lankan vipers (Russell's viper, hump-nosed viper) — different venom families with mechanistically different coagulopathy, a distinction the paper's own subgroup analysis treats as clinically important [Discussion, para. 5].

The review's "textbook path" analog is the overall coagulopathy-resolution estimate (OR 7.71, NNT 2.2) — but this module's subgroup rows show that estimate is not stable across subgroups: the Australian-snake/RCT-leaning subgroups are tight and significant, while the Asian-snake and observational-only subgroups are wide, imprecise, and non-significant, despite point estimates in the same direction [Fig 3]. Mortality shows no benefit on any subgroup [Fig 4]. GRADE certainty for the coagulopathy-resolution outcome is rated very low, driven by risk of bias, inconsistency, and imprecision, with publication bias "strongly suspected" [Table 5].

Divergence 1 — Holla et al. 2018: the single largest, least-precise effect in the corpus

Holla 2018 reports 0/31 resolution events in the ASV-alone arm, producing an OR of 149.21 (95%CI 8.25–2697.75) — a point estimate roughly 18-45× larger than any of the other three studies' ORs, with a confidence interval spanning more than two orders of magnitude [Fig 2]. Sensitivity analysis confirms this single study's outsized influence: removing it drops the overall pooled OR from 7.71 to 4.42 (95%CI 2.06–9.47) — the largest single-study swing of any study in the sensitivity table [Table 2]. It is also the only study using a different outcome measure (20WBCT rather than INR) and the only one whose snake species are unspecified — three separate definitional-drift flags converging on one study.

Divergence 2 — Isbister 2017: only study on a different venom family

Isbister 2017 is the sole trial conducted in Sri Lanka on Daboia russelii (Russell's viper) and hump-nosed viper envenoming, versus the Australian elapid envenoming (brown snakes, tiger snakes, taipans) studied by Isbister 2009/2013 [Table 1]. Its individual OR (2.72, 95%CI 1.23–6.02) is directionally consistent with but numerically much smaller than the Australian studies' ORs (6.61 and 8.18) — and the review's own discussion attributes this to differing venom composition: Australian elapid venoms carry prothrombin activators causing rapid, uniform clotting-factor depletion, while South Asian viperid venoms may have more diverse coagulopathic mechanisms [Discussion, para. 5, citing Isbister 2017 primary study]. This study also carried the overall-highest risk of bias among the four (RoB2: high, on both the coagulopathy and mortality outcomes) due to randomization-process and intervention-deviation concerns [Fig 5; Fig 6].

Adverse-event outlier — anaphylaxis rates diverge sharply by study

OUTLIER (safety signal, not efficacy): Isbister 2017 reported severe anaphylaxis in 11/46 FFP-arm and 17/72 control-arm patients plus 1 TRALI case and 1 ICH case in the FFP arm — substantially higher adverse-event rates than the other three studies combined (1 ICH in Isbister 2009 of unspecified arm; 1 anaphylaxis per arm in Isbister 2013; no serious hypersensitivity reactions in Holla 2018) [Table 3]. Adverse-event reporting was inconsistent across studies, which the review flags as limiting any full safety-profile conclusion [Discussion, Strengths and limitations].

Unresolved heterogeneity — subgroup stratification only partially explains I²=67%

Overall heterogeneity for the primary outcome (I²=67%) drops to 25% when restricted to the 3 INR-based studies and to 0% when restricted to the 2 Australian-snake studies — but rises again to 88% for the 2 Asian-snake studies and 76% for the 2 observational studies [Fig 3; Results §Heterogeneity]. This module surfaces that pattern rather than resolving it: geography/venom-family and study design both partially explain heterogeneity, but no single stratification fully accounts for it, and the review explicitly recommends large-scale multi-centre RCTs with standardized outcome definitions before firmer conclusions can be drawn [Discussion, Implications for practice and future research].

Every citation used above, carried forward from the uploaded paper's own bibliography (Ganessane E, Mohammed Muthanikkatt A, Manu Ayyan S, Abraham SV, Krishnamoorthy Y. Effectiveness of fresh frozen plasma in the resolution of coagulopathy in human patients following hemotoxic snakebites: a systematic review and meta-analysis. BMJ Open 2025; 15:e102745):

1. [1] Better snakebite data needed to save lives and limbs. World Health Organization, 2025.
2. [4] Maduwage K, Isbister GK. Current treatment for venom-induced consumption coagulopathy resulting from snakebite. PLoS Negl Trop Dis 2014; 8:e3220.
3. [8] Isbister GK, Buckley NA, Page CB, et al. A randomized controlled trial of fresh frozen plasma for treating venom-induced consumption coagulopathy in cases of Australian snakebite (ASP-18). J Thromb Haemost 2013; 11:1310-8.
4. [9] Sri Lanka Medical Association. Guidelines for the management of snakebite in hospitals. 2021.
5. [22] Isbister GK, Scorgie FE, O'Leary MA, et al. Factor deficiencies in venom-induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP-10). J Thromb Haemost 2010; 8:2504-13.
6. [26] Isbister GK, Jayamanne S, Mohamed F, et al. A randomized controlled trial of fresh frozen plasma for coagulopathy in Russell's viper (Daboia russelii) envenoming. J Thromb Haemost 2017; 15:645-54.
7. [27] Isbister GK, Duffull SB, Brown SGA, et al. Failure of antivenom to improve recovery in Australian snakebite coagulopathy. QJM 2009; 102:563-8.
8. [28] Holla SK, Rao HA, Shenoy D, et al. The role of fresh frozen plasma in reducing the volume of anti-snake venom in snakebite envenomation. Trop Doct 2018; 48:89-93.
9. [31] Noutsos T, Currie BJ, Lek RA, et al. Snakebite associated thrombotic microangiopathy: a systematic review of clinical features, outcomes, and evidence for interventions including plasmapheresis. PLoS Negl Trop Dis 2020; 14:e0008936.